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ABSTRACT

The invention provides method and kits for detecting a
metallic cation in a sample of a body fluid. The preferred
method and kits include the use of at least two different types
of antibodies having different specificities. In the preferred
method, the sample of body fluid can be contacted with an
effective amount of a capture antibody specific for a naturally occurring polypeptide that can bind the metallic cation
to form a first antigen-antibody complex. An effective
amount of an antibody specific for an epitope on a metallic
cation-naturally occurring polypeptide complex or an antibody specific for a metallic cation is added to the first
antigen-antibody complex to form a second antigen-antibody complex. The amount of the metallic cation in the
sample of body fluid is determined by detecting the amount
of the second antigen-antibody complex.
18 Claims, 5 Drawing Sheets
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MONOCLONAL ANTIBODY ASSAY AND KIT
FOR DETECTING METAL CATIONS IN

assays are not generally convenient and rapid enough to use
for a widespread screening program.
Thus, there is a need for a reliable and rapid screening
and/or diagnostic assay for the presence of lead or other
metallic cations in animals and the environment. In addition
there is a need for an immunoassay for the quantitative
detection of lead and lead-ALAD in blood. There is also a
need for a rapid screening assay in a kit to determine metal
cation concentrations in fluids derived from humans, animals or the environment.

BODY FLUIDS
BACKGROUND OF THE INVENTION
The burdens that exposure to lead and other metal cations
places on society and individuals are massive when one
considers the amount of money required for health care for
those who develop metal cation-induced mental and physical disabilities, and the loss of the productive contributions
that these individuals might otherwise make. For example,
lead exposure can cause acute or chronic manifestations
depending on the amount of lead to which a person has been
exposed, and the duration of exposure. Acute exposure to
lead most often leads to intestinal colic, while chronic
exposure can result in various neurological symptoms, ranging from encephalopathy to psychological deficits, such as
decreased intelligence and behavioral disturbances. Other
metallic cations, such as mercury and cadmium, can also
have adverse effects on nervous, reproductive and immunological systems.
One of the real tragedies in this situation is that, for the
most part, this situation is preventable. If convenient, inexpensive, and reliable screening methods existed, they could
be applied to identifying individuals at risk and to localizing
environmental sources of lead and other metal cations before
irreversible health effects occurs.
Most of the methods, such as atomic absorption spectrometry and anodic stripping voltametry, have been
directed toward detection of metal cations, including lead, in
blood. However, these procedures utilize expensive, specialized equipment that requires highly trained personnel for
proper operation, thus making their use in widespread
screening programs difficult, if not impossible.
As an alternative, other parameters which might serve as
reliable indicators of blood metal cation contamination have
been sought. Those which have been identified for lead
include an increase in erythrocyte protoporphyrin (S.
Piomelle, Low Level Lead Exposure, H. Needleman, editor,
Raven Russ, NY, pp. 67-74 (1980», a decrease in o-aminolevulinic acid dehydratase (ALAD) enzyme activity (S.
Hemberg et al., Lancet, 1:63-66 (1970», and a decrease in
heme synthetase activity (0. Wada et al., Ind. Health,
10:84-92 (1972». Of these, only the increase in erythrocyte
protoporphyrin (EP) has been exploited for use as a screening method to detect the presence of lead in blood. The
major difficulty with this system is that measurement of EP
is not sensitive enough for accurate correlation with a blood
lead concentration below 25 ~g/dl, which is 2.5 times above
the limit recently defined by CDC as the "safe" level oflead
in blood. (L. Alessio et al., British 1. Ind. Med., 38:262-267
(1981).)
ALAD is a zinc-containing enzyme, and inhibition of its
enzymatic activity is thought to result from displacement of
zinc by metal cations including lead. (E. Jaffe et al., Bioi.
Trace Element Res., 28:223-232 (1991).) It is generally felt
that a decrease in ALAD activity is the first measurable
effect of lead contamination and is the most sensitive measure of lead toxicity (Hernberg et aI., cited supra.). A
decrease in ALAD has been implicated in the pathogenesis
of lead poisoning and, thus, may also serve as a reliable
indicator of clinical status of a patient exposed to lead or
other heavy metals. Astrin et al., Ann Ny Acad. Sci., 514:23
(1987). The difficultly with using this parameter for development of a practical assay for blood lead is that enzyme
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The invention provides methods and kits for detecting a
metallic cation in a sample of a body fluid of an animal. The
preferred methods and kits can involve the use of at least two
antibodies having different specificities. These antibodies
fall into two general types with the second including several
subtypes. In a first alternative, the method of the invention
can be conducted by contacting the sample of body fluid
with an effective amount of a first type of antibody, which is
specific for a naturally occurring polypeptide that can bind
the metallic cation to form a first antigen-antibody complex.
The first antibody in this step is functioning as the capture
antibody. A second type of antibody is added in an effective
amount to the first antigen-antibody complex to form a
second antigen-antibody complex. The second antibody is
(1) specific for an epitope on a metallic cation-naturally
occurring polypeptide complex and not substantiaily crossreactive with the naturally occurring polypeptide alone, or
(2) specific for a metallic cation or (3) specific for a
combination of a complexed metallic cation and its coordination site in a metallic cation-naturally occurring polypeptide complex. The metallic cation in the sample of the body
fluid is detected by determining the amount of the second
antigen-antibody complex.
This first alternative of the method of the invention can
also be modified by use of the first and second types of
antibodies in reverse order. In this modification the second
antibody functions as the capture antibody to capture the
metallic cation-naturally occurring polypeptide complex.
In a second alternative, the method of the invention can be
conducted by contacting a sample of the body fluid with one
of the sub-types of the above-described second type of
antibody to form a first antigen-antibody complex. The
second antibody in this step functions as the capture antibody. The same or another subtype of the second type of
antibody is then added to the first antigen-antibody complex
to form a second antigen-antibody complex. If the same
subtype is used, the complex will contain multiple epitopes
of the same structure to enable multiple antibody binding. If
the complex does not contain such epitopes, different subtypes of second type of antibody will be used. The metallic
cation in the sample of body fluid is detected by determining
the amount of the second antigen-antibody complex.
Assays for detecting a metallic cation in a body fluid can
also involve the use of a single type of antibody. The single
type of antibody has specificity for an epitope on a naturally
occurring polypeptide that binds at least two metallic cations. In this version of the assay, a sample of body fluid is
contacted with an effective amount of a first antibody
specific for (1) an epitope or (2) a combination of a complexed metal cation and its complexation site on a metallic
cation/naturally occurring polypeptide complex that binds at
least two metallic cations to form a first antigen-antibody
complex. An effective amount of a second antibody, which
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is of the same type as the first antibody but is not necessarily
the same thing, is added to form a second antigen-antibody
complex. The metallic cation in the sample is detected by
determining the amount of the second antigen-antibody
complex. The first and second antibodies can be specific for
the same or different epitopes.
In a further version, a method for detecting a metallic
cation in a sample of body fluid combines an antibody
binding assay with an enzyme assay. In that method, a
sample of body fluid containing the metallic cation is
contacted with an effective amount of an antibody specific
for an epitope on a metallic cation/enzyme complex or an
epitope on a naturally occurring polypeptide to form an
antigen-antibody complex. The metallic cation is then
removed from the antigen-antibody complex, preferably by
stripping with a chelator or by substitution with a different
metallic cation. The enzyme activity is restored upon
removal of the metallic cation and, preferably, by replacement of the metallic cations with a different metallic cation,
such as the enzyme's natural cofactor. The metallic cation in
the sample is detected by assaying the restored enzyme
activity.
Another method of the invention provides for a determination of whether the animal has been acutely or chronically
exposed to the metallic cation. The steps of the method
include detecting the amount of the metallic cation bound to
a first naturally occurring polypeptide, detecting the amount
of the metallic cation bound to one or more, preferably two
or three, other naturally occurring polypeptides, and comparing the amount of the antibody bound to the first polypeptide to that of the other polypeptides to determine if the
exposure is acute or chronic. The preferred detection method
is that described in the Detailed Description of the Invention.
An antibody (the first type of antibody) specific for a
naturally occurring polypeptide that binds the metallic cation can serve to capture the naturally occurring polypeptide
from the sample of body fluid or, in an alternate version can
also serve as a detection antibody when the capture antibody
is the second type of antibody. The antibody preferably is a
monoclonal antibody and recognizes and binds to the naturally occurring polypeptide whethcr or not it is complexed
with one or more metallic cations. The monoclonal antibody
also preferably binds to the naturally occurring polypeptide
in the body fluid in less than about 10 minutes, and with a
disassociation constant of about 10-4 to 10-13 • The most
preferred antibody is a monoclonal antibody specific for
ALAD.
An antibody (the second type of antibody) (1) specific for
an epitope on a metallic cation-naturally occurring polypeptide complex, or (2) specific for a mctallic cation or (3)
specific for a combination of a complexed metallic cation
and its coordination site in a metallic cation-naturally occurring polypeptide complex functions to allow detection of the
amount of metallic cation present in the sample of body fluid
or, in an alternate version, can also serve as a capture
antibody. An antibody can be specific for the metallic cation
portion or the naturally occurring polypeptide portion or the
combination of the metallic cation and polypeptide metal
complexation site of the metallic cation-naturally occurring
polypeptide complex. When the antibody is specific for the
naturally occurring polypeptide portion, it does not substantially cross-react with the epitopes on the naturally occurring
polypeptide not complexed with the metallic cation (Le.,
alone). When the antibody is specific for the metallic cation,
it binds the metallic cation whether or not complexed with
a naturally occurring polypeptide. When the antibody is
specific for the combination, it only binds with the complex
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at the metal coordination site. The preferred antibody is a
monoclonal antibody specific for a metallic cation. The
especially preferred antibody is a monoclonal antibody
specific for a toxic metallic cation, such as lead, mercury,
cadmium, and gallium.
The method is preferably conducted with one of the
antibodies immobilized on a substrate and the other antibody
labelled with a detectable agent. Antibodies can be immobilized to a variety of solid substrates by known methods.
Suitable solid substrates include materials having a membrane or coating supported by or attached to sticks, cups, flat
packs, or other solid supports. Other solid substrates include
cell culture plates, ELISA plates, tubes, and polymeric
membranes. The preferred solid substrate is a stick coated
with a polymeric membrane. The detectable agent functions
to allow detection of the second antigen-antibody complex
and includes fluorochromes, radioactive labels, biotin and
enzymes. The preferred detectable agent is an enzyme, and
the especially preferred detectable agent is horseradish peroxidase.
The amount of the second antigen-antibody complex
detected is preferably proportional to the amount of metallic
cation present in the sample of body fluid. The amount ofthe
metallic cation present in a sample of body fluid can be
determined by correlating the amount of the second antigenantibody complex detected in the sample with that detected
for standard amounts of the metallic cation-naturally occurring polypeptide complex. Standard solutions of the same
amount of a purified naturally occurring polypeptide that
binds metallic cation are mixed with different concentrations
of the metallic cations ranging from 0.5 ].lg/dl to 50 ].lg/dl.
The standard curve generated can be used to quantitate the
amount of metallic cation in a sample. Alternatively, the
standard solutions can be used to measure the disassociation
constant of antibodies.
The invention also provides a preferred kit containing
eithertwo types of antibodies or one or more versions of the
second type of antibody for detecting a metallic cation in a
sample of body fluid. The kit preferably contains the first
type of antibody and the second type of antibody. Alternatively, the kit can also contain a first antibody and a second
antibody wherein both are specific for an epitope on a
metallic cation/naturally occurring polypeptide that binds at
least two metallic cations. A kit can also contain an antibody
specific for a naturally occurring enzyme that binds the
metallic cation or an antibody specific for a metallic cation
enzyme complex, and substrates for measuring the enzyme
activity.
One of the antibodies in the kit is preferably immobilized
and the other antibody is labelled with a detectable agent.
When the detectable agent is an enzyme, a means for
detecting the detectable agent is supplied with the kit. The
preferred means for detecting the detectable agent is an
enzyme substrate that changes color upon contact with the
enzyme. The kit also optionally includes standard amounts
of metallic cation-naturally occurring polypeptide complexes andlor a chart with visual representations of the
amount of colored product corresponding to the standard
amounts of the metallic cation-naturally occurring polypeptide complexes andlor can be quantified spectrophotometrically.
The kits provide a rapid diagnostic andlor screening
method for determining contamination of animals with
metallic cations, especially toxic metallic cations. The kits,
as disclosed herein, are especially advantageous because
they provide a simple and inexpensive method to measure a
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large number of samples of body fluid for metal ion contamination. The kits, as disclosed herein, are also very
versatile in that the kit can be designed to be quantitative or
qualitative, or for use in the field or in the laboratory.

essential for the activity of the naturally occurring polypeptide. The naturally occurring polypeptides can function as
indicators of the presence of and the amount of the metallic
cation in a body fluid, such as blood. In the case of some
metallic cations, the naturally occurring polypeptide can
serve to concentrate the metallic cation from the liquid
portion of the blood serum. In addition, the binding of some
metallic cations to the polypeptide can inactivate the function of the polypeptide. The inactive naturally occurring
proteins can contribute to pathogenesis associated with
exposure to metallic cations and serve as an indication of the
clinical status of the animal. A naturally occurring polypeptide is one that is formed by the animal and is usually present
in sufficient concentrations to be detected in the body fluid.
The naturally occurring polypeptide is capable of binding
at least one, and preferably more than one different metallic
cations to form a metallic cation-naturally occurring
polypeptide complex. A naturally occurring polypeptide can
normally contain a metallic cation cofactor that can then be
displaced by binding to different metallic cation. For
example, a naturally occurring polypeptide can have Zn+2
cations as the native cofactor but also can bind to lead,
mercury and cadmium cations which replace the Zn+2 cations. Replacement of the native cofactor metallic cation with
another metal cation can lead to inactivation of the function
of the polypeptide. For example, replacement of Zn+2 in
ALAD by Pb+2 results in an inactivation of ALAD enzyme
activity.
Preferably, the naturally occurring polypeptide can bind
an amount of the metallic cation that is proportional to the
amount of metallic cation in a sample of body fluid. The
naturally occurring polypeptide coordinates or binds the
metallic cation with sufficient strength so that the metallic
cation is retained by the polypeptide even though the
polypeptide is washed with buffer solution several times.
Preferably, the naturally occurring polypeptide and the
metallic cation formed a coordinate covalent bond. A naturally occurring polypeptide binds or coordinates with the
metallic cation preferably with an disassociation constant of
about 10-5 to 10- 10 .
The metallic cations bound or coordinated by a naturally
occurring polypeptide include cations of alkaline metals,
transition metals, i.e., those elements in the periodic table
with their outer most electrons in d" orbitals, the Group IlIa
metal!metalloids (B, AI, Ga, In, and TJ), the Group IVa
metal/metalloids (Si, Ge, S, and Pb), the Group Va metal!
metalloids (As, Sb and Bi). The metallic cation can be
monovalent or multivalent, but is preferably divalent and
can be bound to another organic moiety, e.g., methylmercury. More preferably, the metallic cation is a toxic metallic
cation known to have toxic effects on humans and other
animals, as described in Handbook on the Toxicology of
Metals, 2nd Edition, Eds: Friberg, Nordberg, Vouk, Elsevier,
Amsterdam (1986). Toxic metallic cations include those that
bind to sulfhydryl containing polypeptides including but not
limited to lead, mercury, cadmium, copper, methylmercury,
and others that do not bind sulfhydryl groups. A naturally
occurring polypeptide is preferably capable of binding or
coordinating with lead, mercury, methylmercury, cadmium
and/or gallium cations.
Suitable examples of naturally occurring polypeptides
that bind metallic cations include o-aminolevulinic acid
dehydratase (ALAD), hemoglobin (Baltrop et al., Experientia, 28:76 (1972», heme synthetase (Erikson, Scand. 1.
Cline. Lab. Investigations, 4:55-62 (1952», coproporphyrinogen decarboxylase (Goldberg et al., Blood, 11 :821
(1956», ALA-synthetase (Drussel et al., Biochem. 1., 63:72
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DETAILED DESCRIPTION OF THE DRAWINGS
FIG. 1 shows inhibition of binding of mAb 4AlO and
mAb lFlO to immobilized BSA-glutathione-HgCI by
soluble mercuric chloride.
FIG. 2 shows detection of mercury in the EPA Quality
Control sample by ELISA.
FIG. 3 shows a comparison of mercury detection by
ELISA and atomic absorption.
FIG. 4 shows inhibition of binding of mAb 1C3 and mAb
14FIl to immobilized BSA-glutathione Pb+ 2 by soluble lead
acetate.
FIG. 5 shows a Western blot of metal-contaminated red
celllysates. Metal-containing proteins were detected with an
antibody specific for lead cations. Hemoglobin is shown at
the arrow. Lane 1 represents molecular weight standards;
Lane 2: red cell lysate depleted of lead; Lane 3: red cell
lysate with 55 ~g/dl lead; Lane 4: red cell lysate with 20
~g/dllead; and Lane 5: red cell lysate with 5 ~g/dllead.
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DETAILED DESCRIPTION OF THE
INVENTION
Methods and kits provided for in the invention allow for
the detection of metallic cations in a sample of body fluid.
The preferred method and kit involve the use of at least two
antibodies having different specificities, i.e., a selection from
the two types of antibodies. One type of antibody is specific
for a naturally occurring polypeptide that binds metallic
cations present in the body fluid. The other type of antibody
is composed of three subtypes of differing specifications.
The first subtype is specific for an epitope on a metallic
cation-naturally occurring polypeptide complex. The second
subtype is a specific for a metallic cation. The third subtype
is a specific for a combination of a complexed metallic
cation and its complexation site in a metallic cation-naturally occurring polypeptide complex. The antibody specific
for metallic cation-naturally occurring polypeptide complex
can be specific for either the metallic cation portion or the
naturally occurring polypeptide portion of the complex. The
two antibodies are combined in a preferred method that
allows the detection of the metallic cation in a body fluid by
determining the amount of the metallic cation bound to a
naturally occurring polypeptide present in the body fluid.
A. Antibodies to Naturally Occurring Polypeptides That Can
Bind the Metallic Cation
Antibodies having specificity for a naturally occurring
polypeptide that can bind a metallic cation are useful in
method and kits of the invention. Preferably, the antibody is
a mammalian IgG, IgA or IgM antibody, and more preferably the antibody is a monoclonal antibody. A monoclonal
antibody specific for a naturally occurring polypeptide,
preferably has a disassociation constant about 10-5 to 10-10 .
A disassociation constant is the ratio of the multiplication
product of the concentrations of all reactants to the multiplication product of the concentrations of all products found
in an equilibrium mixture, as described by the method of
Friguet et al., 1. Immunol. Methods, 77:305 (1985).
Many naturally occurring polypeptides found in animals
are capable of binding one or more metallic cations. These
naturally occurring polypeptides are also known as metalloproteins. A metallic cation typically serves as a cofactor
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(1956)), human serum albumin, glutathione, pyrimidine 5'
culture fluid containing monoclonal antibodies with the
nucleotidase, protein kinase C, and metallothioneins (M.
naturally occurring polypeptide to form an antigen-antibody
Karin, Cell, 41:9 (1985)). The preferred naturally occurring
complex, separating the antigen-antibody complex, and then
assaying the antigen-antibody complex for functional activpolypeptide that binds metallic cations is D-aminolevulinic
5 ity. For example, if the naturally occurring polypeptide is an
acid dehydratase (ALAD).
enzyme, the antigen-antibody complex can be assayed for
The naturally occurring polypeptide that binds metallic
enzymatic activity.
cations can be isolated from animal species, including
Suitable monoclonal antibodies are those specific for
humans, cows, fish, and other vertebrates. The naturally
ALAD, hemoglobin, glutathione, human serum albumin,
occurring polypeptide is isolated, purified, and used as an
immunogen to form antibodies. Purification methods for 10 and the metallothioneins. The preferred monoclonal antipolypeptides that bind metallic cations from body fluids are
body is specific for ALAD. Suitable polyclonal antibodies
standard methods, including ammonium sulfate precipitaare those to human serum. Some of these antibodies are
tion and chromatography, such as ion exchange, affinity and
commercially available.
In the preferred version, monoclonal antibodies to the
HPLC chromatography.
A naturally occurring polypeptide that binds the metallic 15 naturally occurring polypeptideALAD are formed. ALAD is
cations is used as an immunogen to form polyclonal and
an enzyme that is known to bind Zn+2 cations as its native
monoclonal antibodies. The immunogen can contain a single
metallic cation cofactor, however, the enzyme is also known
to bind or coordinate with lead, mercury, cadmium, or
polypeptide or a plurality of polypeptides such as found in
a red cell lysate or serum. The immunogen can also be a
copper as well. Bernard & Lauwerys, Ann. NY Acad. Sci.,
naturally occurring polypeptide complexed with one or more 20 51:41--47 (1987). BovineALAD is purified from erythrocyte
cell lysates, as described by the method of Fujita et al.,
metallic cations. Typically an animal that is a different
Biochem. Biophys. Acta, 678:39-50 (1981) using ammospecies than that from which the naturally occurring
nium sulphate precipitation and heat treatment followed by
polypeptide is isolated is immunized with the purified
DEAE and ultragel ACA34 chromatography. An effective
polypeptide. The immunogen is administered parenterally,
most often, either subcutaneously or intraperitoneally in an 25 amount of purified bovine liver ALAD is injected with
adjuvant. Administration of the immunogen is repeated
adjuvant into mice. Polyclonal serum can be harvested from
periodically and preferably for at least four injections. After
the mice at this point and the presence of ALAD-specific
repeated immunizations, polyclonal serum can be harvested
antibodies is monitored by ELISA. The spleen is fused to
from the animal.
form hybridoma cell lines. Monoclonal antibodies specific
Preparation of monoclonal antibodies is achieved by the 30 for ALAD, whether or not complexed with lead, are
selected. Monoclonal antibodies are further selected for
standard technique, as described in Antibodies: A Laboratory Manual, Harlow & Lane; Cold Spring Harbor (1988).
specificity for the biologically active form of ALAD by
Briefly, spleens are harvested from animals immunized with
assaying ALAD monoclonal antibody complexes for ALAD
the immunogen as described above. Spleen cells are sepaenzyme activity by the method of Tsukomoto et al., Biorated and fused with the immortal myeloma cells using 35 chem. Biophys. ACTA, 570:167-178 (1979). The preferred
monoclonal antibody specific for bovine ALAD also recogpolyethylene glycol. The fused hybridoma cells are selected
nizes and binds to human ALAD.
and cultured in vitro. The hybridoma cell culture fluids are
tested for the presence of hybridoma antibodies having a
The invention also provides a method for identifying
certain specificity.
naturally occurring polypeptides that can bind metallic catThe selection technique for identifying the appropriate 40 ions present in body fluids. The method involves using a
first type monoclonal antibody is an important aspect for
Western blot assay with monoclonal antibodies specific for
determining the immunospecificity desired according to the
metallic cations. Samples of a body fluid from an animal are
invention. The hybridoma cells culture fluids are tested for
treated so that any cells in the body fluid are lysed. The
the presence of antibodies specific for the naturally occursample of the body fluid is then incubated with various
ring polypeptide with an ELISA conducted by standard 45 concentrations of a metallic cations, preferably the concenmethods.
trations range from 0.5 J.lg/dl to 50 J.lg/dl of the metallic
Additional screening methods can also be employed to
cation or can be obtained from animals dosed experimentally with varying amounts of metallic cations. The metallic
further select the monoclonal antibody having the desired
specificity. One or more of these screening methods can be
cation-treated sample is then subjected to electrophoresis.
employed to select a monoclonal antibody having a particu- 50 The proteins separated by electrophoresis are transferred to
lar specificity. Those additional screening methods include
a nitrocellulose membrane. The separated proteins on the
nitrocellulose membrane are then incubated with monoscreening for monoclonal antibodies that can also bind to the
naturally occurring polypeptide when it is a part of a metallic
clonal antibodies labelled with a detectable agent and specation-naturally occurring polypeptide complex. Another
cific for the metallic cation added to the initial solution.
preferred monoclonal antibody recognizes and binds the 55 Separated proteins binding to the monoclonal antibodies
specific for the metallic cation are identified by detecting the
naturally occurring polypeptide whether or not it is complexed with one or more metallic cations. In addition, the
detectable agent. The polypeptides that have bound the
hybridoma cell culture fluid can also be selected for monometallic cation are identified by molecular weight and can be
clonal antibodies that are specific for the biologically active
eluted from an electrophoresis gel run in parallel. The
form of the naturally occurring polypeptide. Alternatively 60 polypeptides that bind metallic cations can be identified by
and optionally, a monoclonal antibody specific for a natucomparison to a panel of known polypeptides that bind
rally occurring polypeptide that binds the metallic cation can
metallic cations to help identify the polypeptide. Comparibe screened for specificity for the naturally occurring
son methods can include Western blots, PAGE, HPLC, other
polypeptide from several different species of animals.
chromatography. Any new polypeptides identified as bindThe selection for a monoclonal antibody specific for 65 ing to metallic cations can be further characterized by
biologically active forms of the naturally occurring polypepstandard methods for amino acid analysis and enzyme
tide can be accomplished by contacting the hybridoma cell
activity.
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The method allows the identification and characterization
of naturally occuning polypeptides that can bind metallic
cations and also allows the identification of naturally occurring polypeptides that can bind metallic cations present at
very low concentrations.
5
B. Antibodies that Can Detect the Presence of the Metallic
Cation
Antibodies of the second type are useful in the methods
and kits of the invention. The antibodies are preferably
mammalian antibodies of the IgG, IgA and IgM class, and 10
more preferably are monoclonal antibodies. One version of
this type of antibody is specific for an epitope either as the
metallic cation portion or as the naturally occuning polypeptide portion of the metallic cation-naturally occuning
polypeptide complex. An epitope on the metallic cationnaturally occuning polypeptide complex can be (1) the 15
metallic cation or (2) peptide epitope or (3) the metallic
cation-peptide coordinate epitope recognized only when the
naturally occuning polypeptide is complexed with the
metallic cation. The antibody can also be specific for a
metallic cation whether or not bound to a naturally occuning 20
polypeptide. The preferred monoclonal antibodies are specific for a metallic cation and also, more preferably, bind to
and recognize the metallic cation portion of a metallic
cation-naturally occuning polypeptide complex. The monoclonal antibodies are specific for an epitope only found on a 25
metallic cation-naturally occuning polypeptide complex,
Le., the monoclonal antibody does not substantially crossreact with the naturally occuning polypeptide not complexed with the metallic cation (i.c., alone).
Monoclonal antibodies specific for metallic cations or for 30
a metallic cation-naturally occuning polypeptide complex
also preferably do not substantially cross-react with other
metallic cations or other metallic cation-naturally occuning
polypeptide complexes. A monoclonal antibody is substantially non-crossreactive with other antigens if it does -not 35
significantly react with the antigen over background levels
in a standard ELISA reaction. Preferably, a non-crossreaetive antigen binds to the antibody with a disassociation
constant of 10-4 or less. Monoclonal antibodies of the
invention preferably have a disassociation constant of about 40
10-4 to 10-13 , and preferably about 10-7 to 1O-!1. The
monoclonal antibody specific for a metallic cation or a
metallic cation-naturally oceuning polypeptide complex can
be used to detect the amount of a metallic cation present in
a sample of a body fluid or can be uscd as capture antibody 45
to remove metallic cation containing naturally occuning
polypeptides from the sample of body Ouid. The preferred
monoclonal antibodies arc capable of dctecting metallic
cations in a sample of body Ouid with as low as I Ilg/dl (10
50
ppb) of metallic cation.
Metallic cations include cations of the alkali earth metals,
the transition metals, i.e., those clements in the periodic
table with their outermost electrons in the d n orbitals, Group
IIIa metal/metalloids (B, AI, Ga, In, and TJ), Group IVa
metal/metalloids (Si, Ge, S, and Pb), and Group Va metal/55
metalloids (As, Sb and Bi). The metallic cation can be
monovalent or multivalent, but arc preferably divalent and
can be bound to another organic moiety, e.g. methylmercury.
More preferably, the metallic cation is a toxic metallic cation
known to be harmful to humans and other animals, as 60
described in Handbook on the Toxicology of Metals, cited
supra. Typically, toxic metallic cations are those that bind to
sulfhydryl containing polypeptides including lead, mercury,
cadmium, copper, and methylmercury. The preferred metal65
lic cations are lead, mercury, cadmium, and gallium.
Suitable examples of monoclonal antibodies specific for
metallic cations include monoclonal antibody 4AlO specific

10
for mercury. This monoclonal antibody has a disassociation
constant of 2.3xlO-9M for HgCI 2 . This monoclonal antibody does not substantially cross-react with barium chloride, cadmium chloride, chromic chloride, copper chloride,
ferrous sulfate, gold chloride, nickel chloride, selenium
oxide, silver chloride, and zinc chloride. Monoclonal antibodies to lead have also been generated. The preferred
monoclonal antibody is specific for Pb and does not crossreact with other similarly structured metal ions.
Monoclonal antibodies specific for lead and mercury
cations have been deposited with the American Type Culture
Collection (ATCC) on Mar. 13, 1990. Monoclonal antibody
BN No. 4AI0B4, ATCC Accession No. HB 10381, has a
dissociation constant for mercury cation of less than about
10-9 but does not bind cadmium, copper, zinc, lead, nickel
and cobalt cations to any appreciable extend.
Antibodies of the invention can also bind to an epitope of
a metal cation naturally occuning polypeptide complex such
as Pb complexed with ALAD. Preferably, the antibody does
not substantially crossreact with other metallic cation naturally occuning polypeptide complexes such as Zn complexed with ALAD. Optionally, the antibody may also be
capable of binding to the uncomplexed metallic cation. This
antibody is also substantially non-crossreactive with the
naturally occuning polypeptide uncomplexed with the
metallic cation such as ALAD without Pb. The naturally
occuning polypeptide complexed with the metal cation can
also be an enzyme so that the antibodies can recognize a
metal cation enzyme complex. A preferred monoclonal
antibody is a monoclonal antibody specific for lead complexed with ALAD. An antibody with specificity for leadALAD and designated 14F11 has been deposited with the
American Type Culture Collection, Rockville, Md. on Apr.
16, 1993 and given Accession No. HB 11330.
A metallic cation-naturally occuning polypeptide complex can be formed by incubating a naturally occuning
polypeptide that binds the metallic cation with the metallic
cation or can be formed by exposure of the animal to the
metallic cation in vivo. A naturally occuning polypeptide
that is known to bind metallic cations can be isolated and
purified from an animal or a naturally occuning polypeptide
that binds metallic cations can be identified by a method of
the invention. A naturally occuning polypeptide can have a
native metallic cation cofactor and can bind to a different
metallic cation which then displaces the native metallic
cation cofactor. A naturally occurring polypeptide binds to
the metallic cation with sufficient strength to withstand
several washings of the complex. Preferably, a naturally
occuning polypeptide binds to or coordinates with the
metallic cation with a disassociation constant of 10-4 to
10-13 .
Suitable examples of naturally occuning polypeptides
that bind to metallic cations include o-aminolevulinic dehydratase (ALAD), hemoglobin, heme synthetase, coproporphyrinigen decarboxylase, ALA synthetase, human serum
albumin, glutathione, pyrimidine 5' nucleotidase, protein
kinase C, and metallothioneins. The preferred metallic cation-naturally occuning polypeptide complex is lead-ALAD.
The strategy for forming monoclonal antibodies immunoreactive with bare or uncomplexed metallic cations is that
described in copending application U.S. Ser. No. 324,392
filed on Mar. 14, 1989. The monoclonal antibodies to
metallic cations are formed in response to an immunogen
having characteristics that allow for the metallic cation to
remain in a'substantially exposed state so that it is available
to react with the cells of the immune system.
The immunogen compounds for generation of the specific
immunogenicity of the monoclonal antibodies for metallic
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(KLH). Once formed, the carrier spacer arm is incubated
cations are based upon the hapten-carrier concept. In the
present invention, hapten is coordinated at the end of a
with the metallic cation to form an immunogen. The immuspacer arm covalently bonded to a carrier. The spacer arm is
nogen is administered to an animal parenterally, most often,
adapted so as to be semi-rigid and to hold the metallic cation
either subcutaneously or intraperitoneally with an adjuvant.
in an exposed position relative to the carrier. This arrange- 5 Administration of the immunogen is repeated at least four
ment is also adapted to maintain the metallic cation in a
times. After repeated immunization, polyclonal sera can be
substantially exposed state. These factors combine substanharvested.
tially to avoid chelating, uncovering or inclusion of the
Monoclonal antibodies are formed by standard methods,
metallic cation by the spacer and/or the carrier.
as described previously. Briefly, spleens from the immuThe spacer arm, as characterized above, may be an 10 nized animals are harvested and spleen cells separated.
oligopeptide, an aliphatic compound, or an aliphatic fragSpleen cells are fused with myeloma cells to form hybriment. In the later two instances, the aliphatic compound or
doma cells. Hybridoma ceIls are selected and incubated in
fragment may be covalently bonded to the carrier by means
vitro. The presence of monoclonal antibodies specific for
of a Schiff base reaction with an aldehyde group; an amide
metallic cations in the hybridoma cell culture medium is
reaction with an amine or carboxylic acid group using a 15 assayed by ELISA. Hybridoma secreting monoclonal antipeptide activator such as carbodiimide, acid chloride and the
bodies are selected for specificity to metallic cations.
like; and an ester reaction with a hydroxyl or carboxylic acid
The monoclonal antibodies can be selected by one or
group using a Shotten-Bauman reaction or azide or acid
more selection techniques. One selection technique selects
catalysis reaction; a sulfide reaction using sulfide coupling
for the ability of the monoclonal antibodies to immunoreact
agent or other known coupling reactions for joining organic 20 with the metallic cation and to not substantially cross-react
molecules to proteins. See, for example, E. A. Kabat,
with the carrier spacer arm conjugate. The monoclonal
Structural Concepts in Immunology and Immunochemistry,
antibodies can also be selected to not substantially cross2nd edition, Holt, Rheiner & Winston, New York (1976) (a
react with other metallic cations. A monoclonal antibody is
review text of such methods); and Jaime Eyzaguirre, Cheminot substantially crossreactive with an antigen if it doesnot
cal Modification of Enzymes: Active Site Studies, Chichester, 25 react with that antigen significantly above background level
Westsussex, England, Halsted Press (1987). The oligopepin a standard ELISA assay. Preferably, the monoclonal
tide, aliphatic compound or fragment will contain backbone
antibody binds to a non-crossreactive antigen with a disasgroups which provide semi-rigidity to the spacer arm. Presociation constant of 10-4 or less. The monoclonal antibodferred groups for developing this semi-rigidity include pepies can also be selected to bind to the metallic cation portion
tide bonds, olefin bonds, olefinic conjugated systems, ester 30 of a metallic cation-naturally occurring polypeptide comgroups and enone groups. Optionally, one or more aromatic
plex. The preferred monoclonal antibody is specific for a
rings can be incorporated into the spacer arm to stimulate the
metallic cation, does not substantially cross-react with the
development of an immune response.
carrier spacer arm or other metallic cations, and binds to the
In general, the oligopeptide spacer arm has the following
metallic cation portion of a metallic cation-naturally occurformula:
35 ring polypeptide complex.
A preferred application contemplates the production of
-X-(R)-Y
monoclonal antibodies specific for the mercuric cation or
another toxic heavy metal cation. The heavy metal cation is
wherein X is a coupling group that will bond to the carrier,
combined into an immunogen compound, as described
R is one or more amino acid residues, and Y is the Lewis
40 above, and suspended in aqueous medium. The preferred
acid or base group for metallic cation coordination.
protein carrier for the immunogen compound in this instance
In general, the aliphatic compound or fragment spacer
is
keyhole limpet hemocyanin. The preferred spacer arm in
arm has the following formula:
this instance is an oligopeptide which has sulfhydryl groups
capable of coordinating with the heavy metal cation. Glu-X-(Q)-Z
45 tathione is especially preferred as the spacer arm. The
wherein X is a coupling group that will bond to the carrier,
suspension of the immunogen compound is used to immuQ is a semi-rigid aliphatic moiety containing ester amide
nize a host mammal, such as a mouse, following the techketo, olefin or aromatic groups and the like, and Z is the
niques outlined above. The laboratory strain of mouse
designated BALB/c is particularly preferred.
Lewis acid or base group for metallic cation coordination.
Antibody producing cells of the immunized host spleen
Preferably, an oligopeptide or aliphatic compound is used 50
as the spacer arm for a metallic cation. In this instance, the
are collected and converted into a suspension. These spleen
pendant Lewis base groups will preferably be positioned at
ceIls are fused with immortal cells. Preferably myeloma
the spacer arm and remote from the carrier. These Lewis
cells of the same animal species as the immunized host are
base groups function as a coordination site or sites for the
used as a fusion partner. Typically, a cell fusion promoter,
metallic cation. It is preferable that the deformity of the 55 such as polyethylene glycol, is employed to cause formation
electron shells of the Lewis base groups and the metallic
of the hybridoma cells. The hybridoma cells are diluted and
cations be approximately similar. Accordingly, sulfur groups
cultured in a medium which does not allow for the growth
can serve as the Lewis base groups when the metal cations
of unfused cells.
are transition metals or inert transition elements. NitrogenThe monoclonal antibodies produced and secreted by the
containing groups are preferably employed as Lewis base 60 hybridomas are thereafter assayed for the ability to bind
groups when aluminum, lithium, boron, strontium, and
specifically with the heavy metal cations used for immunimagnesium are the metallic cations.
zation. They are further selected for lack of cross-reactivity
Carrier molecules are typically large molecular weight
with the carrier and with carrier spacer arm. The preferred
proteins that can function to concentrate the carrier spacer
assay method in this context is an enzyme-linked immunarm metallic cation complex. Suitable carrier molecules 65 osorbent assay.
include proteins that are not enzymatically active such as
The resulting monoclonal antibodies are specific for toxic
bovine serum albumin (BSA) or keyhole limpet hemocyanin
heavy metal cations and exhibit strong disassociation con-
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stants for the heavy metal cations when in the presence of
teins and polypeptides present in the sample. The antibody
spacer arm, the spacer arm carrier composition, and other
will preferably bind the naturally occurring polypeptide
similarly structured cations. Preferred monoclonal antibodwhether or not it is complexed with one or more metallic
ies are selectively immunoreactive with cations of mercury,
cations. A polyclonal antiserum to red cell proteins or serum
lead, cadmium, strontium, nickel, cobalt, gold, or arsenic. 5 proteins can be used to effectively capture substantially all
Polyclonal and monoclonal antibodies specific for a
polypeptides that bind the metallic cation and provides for a
metallic cation-naturally occurring polypeptide complex can
sensitive detection of the metallic cation contamination of
be formed by immunizing an animal with the naturally
the body fluid. Preferably, the antibody is a monoclonal
occurring polypeptide complexed with the metallic cation,
antibody and, more preferably, is a monoclonal antibody
as described previously. The antibodies formed and selected 10 specific for an epitope shared by the naturally occurring
can be specific for the metallic cation portion of the metallic
polypeptide from many animal species. The especially precation-naturally occurring polypeptide complex or a peptide
ferred monoclonal antibody is specific for ALAD. An effecepitope on the naturally occurring polypeptide portion of the
tive amount of the antibody is that amount of antibody that
metallic cation-naturally occurring polypeptide complex. A
is sufficient to bind substantially all of the naturally occurmonoclonal antibody specific for an epitope on the naturally 15 ring.polypeptide from the sample of body fluid. An effective
amount of the antibody can be determined by measuring the
occurring polypeptide portion of the complex does not
substantially cross-react with epitopes on the naturally
total protein level in the sample of body fluid by standard
occurring polypeptide not complexed with the metallic
methods.
The second type of antibody is added to the first antigencation. The preferred monoclonal antibodies are selected for
specificity for an epitope found on the metallic cation- 20 antibody complex and allows the determination of the
amount of the metallic cation present in the sample. The
naturally occurring polypeptide complex and not found on
the naturally occurring polypeptide complexed with a difantibody can be specific for the metallic cation portion or for
ferent metallic cation. The monoclonal antibodies can also
the naturally occurring polypeptide portion or for the combe further selected to not substantially cross-react with other
bination of the metallic cation and coordinate polypeptide
metallic cation-naturally occurring polypeptide complexes. 25 portion of the metallic cation-naturally occurring polypepThe especially preferred monoclonal antibody is a monotide complex. The antibody can also be specific for a
clonal antibody that is specific for lead-ALAD complex and
metallic cation not complexed with a naturally occurring
does not substantially cross-react with ALAD.
polypeptide. When the antibody is specific for the naturally
occurring polypeptide portion or the combination of the
C. Method for Detecting a Metallic Cation in a Body Fluid
The invention provides a preferred method for detecting 30 metallic cation-naturally occurring polypeptide complex, it
a metallic cation in a sample of a body fluid utilizing two
does not substantially cross-react with the naturally occurdifferent antibodies. The method involves contacting an
ring polypeptide not complexed with the metallic cation
(Le., alone). The preferred antibody is a monoclonal antieffective amount of a capture antibody of the first type with
the sample of body fluid suspected of containing the metallic
body for a metallic cation. The especially preferred antibody
cation to form a first antigen-antibody complex. This step 35 is a monoclonal antibody for a toxic metallic cation, such as
functions to capture a naturally occurring polypeptide that
lead, cadium, mercury, and gallium. An effective amount of
binds the metallic cation from the body fluid. Then, an
the antibody specific for an epitope on a metallic cationeffective amount of the second type of antibody is added to
naturally occurring polypeptide complex is that amount that
the first antigen-antibody complex to form a second antigenis sufficient to bind substantially all of the first antigenantibody complex. This antibody can be any of the three 40 antibody complex.
The preferred method of the invention can also be conspecific SUbtypes mentioned above. The antibody can also be
specific for an epitope formed in response to a metallic
ducted in reverse order. A sample of the body fluid containcation bound to a spacer arm-carrier conjugate immunogen.
ing the metallic cation bound to a naturally occurring
The second antigen-antibody complex includes the first type
polypeptide can first be contacted with a capture antibody
of antibody, the naturally occurring polypeptide, the metallic 45 that is of the second type to form a first antigen-antibody
complex. For example, monoclonal antibodies specific for
cation and the second type of antibody. The amount of the
lead can be used to bind lead and lead complexed with the
metallic cation in the sample of body fluid is determined by
detecting the amount of the second antigen-antibody comnaturally occurring polypeptides in the sample of the body
plex. The amount of the second antigen-antibody complex is
fluid. An antibody of the first type can then be added to form
preferably proportional to the amount of the metallic cation 50 the second antigen-antibody complex. The amount of the
metallic cation in the sample of body fluid is determined by
in the sample.
A sample of the body fluid suspected of containing a
detecting the amount of second antigen-antibody complex.
metallic cation is obtained from an animal species. All
The amount of the second antigen-antibody complex is
animal species can contain metallic cations, especially toxic
preferably proportional to the amount of metallic cation
metallic cations. Suitable body fluids include any fluid that 55 present in the sample of body fluid.
The preferred method of the invention can also be pracmight contain a naturally occurring polypeptide that binds
the metallic cation. The preferred body fluids are those that
ticed through use of the second type of antibody as both the
capture and detection antibody. If multiple epitopes of the
are easily obtained from the animal, including blood, urine,
same structure appear on the metallic cation-naturally occursaliva, and cerebral spinal fluid. Preferably the sample of
body fluid is treated with a lysing agent to lyse cells present 60 ring polypeptide complex, the same subtype of second
antibody can be used twice. If not, then differing subtypes
in the body fluid. Cells in the sample of body fluid can also
contain a naturally occurring polypeptide that bind the
will be used. Capture and detection procedures are conmetallic cation. Suitable lysing agents include surfactants
ducted as described for the foregoing versions of the method
such as Tween 80, Nonidet p40, Triton X-lOG, and the like.
of the invention.
The first type of antibody selectively binds to the naturally 65
The antibody used first to contact the sample of the body
fluid is preferably immobilized onto a solid substrate. The
occurring polypeptide in the sample of the body fluid to
antibody can be immobilized onto a solid substrate by a
isolate the naturally occurring polypeptide from other pro-
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variety of methods, as described in Antibodies: A Laboratory Manual, cited supra.
Suitable solid substrates include materials having a membrane or coating supported by or attached to sticks, synthetic
glass, agarose beads, cups, flat packs, or other solid supports.
Other solid substrates include cell culture plates, ELISA
plates, tubes, and polymeric membranes. The preferred solid
substrate is a stick coated with a polymeric membrane.
An antibody that is added to the first antigen-antibody
complex to form a second antigen-antibody complex is
preferably labelled with a detectable agent so that the second
antigen-antibody complex can be easily detected. The antibody can be labelled with a detectable agent by standard
methods, as described in Antibodies: A Laboratory Manual,
at pages 319-358, cited supra. The method for labelling the
antibody with a detectable agent depends on the type of
detectable agent and is conducted so that the labelling of the
antibody does not interfere with the capability of the antibody to bind to the antigen.
Suitable detectable agents include enzymes, radioactive
labels, fluorochromes, and biotin. The preferred detectable
agents are enzymes, such as horseradish peroxidase, alkaline
phosphatase, and ~-galactosidase.
The means for detecting the second antigen-antibody
complex depend on the detectable agent coupled to the
antibody. If the detectable agent is a radioactive label, like
1125 or S35, then the second antigen-antibody complex is
detected by measuring radioactive decay in a scintillation
counter. If the detectable agent is a fluorochrome, the second
antigen-antibody complex is detected by measuring fluorescent energy emissions spectrophotometrically. If the detectable agent is an enzyme, the second antigen-antibody complex is detected by enzymatic conversion of a substrate.
In a preferred version, the detectable agent is an enzyme
and the means for detecting the detectable agent is a substrate for that enzyme. The substrate is preferably a compound that changes color as a result of the enzymatic
activity. A sufficient amount of the substrate is added to
ensure that the amount of substrate converted is proportional
to the amount of the second antigen-antibody complex
present in the sample.
The metallic cation present in the sample of body fluid can
be detected by determining the amount of the second antigen-antibody complex and comparing it to a standard curve
that correlates the amount of the second antigen-antibody
complex with a known concentration of the metallic cation.
The immunoassay, as described above, can be run with
standard amounts of the naturally occurring polypeptide
purified and mixed with different concentrations of the
metallic cation ranging from about less than 0.5 Ilg/dl to 50
Ilg/dl. For example, standard solutions containing the same
amount of purified ALAD can be mixed with different
concentrations of lead cations ranging from about 0.5 Ilg/dl
up to 50 Ilg/dl. These standard solutions are then contacted
with an antibody specific for ALAD to form a first antigenantibody complex. An antibody specific for the lead labelled
with horseradish peroxidase is then added to the first antigen-antibody complex to form the second antigen-antibody
complex. The amount of the second antigen-antibody complex is measured by conversion of the substrate for horseradish peroxidase, 2,2'-azino-di-[3-ethyl-benzothiazoline
sulfonate(6)] (ABTS). ABTS is converted to a colored
product which is measured spectrophotometrically at 405
nanometers. A standard curve is constructed by plotting the
amount of lead cation added to the original sample against
the amount of substrate converted.
In a preferred version, the method detects the amount of
lead cations present in human blood. A blood sample is
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obtained and treated with Triton X-lOO to lyse the red blood
cells. The sample is then contacted with an antibody specific
for ALAD immobilized on an ELISA plate to form a first
antigen-antibody complex. The plate is then washed to
remove uncomplexed proteins, and an antibody specific for
lead and labelled with horseradish peroxidase is added to the
first antigen-antibody complex. After incubation and washing, the substrate for horseradish peroxidase, ABTS is
added. Conversion of the substrate to the product is measured spectrophotometrically at 405 nanometers. The
amount of lead cation in the blood sample is determined by
reference to the standard curve.
This method can be used to detect a plurality of different
metallic cation-naturally occurring polypeptide complexes
in a body fluid. For example, immunoassays can be run
concurrently using several different antibodies specific for
different naturally occurring polypeptides that bind to metallic cations. For example, the immunoassay can be run with
either an antibody specific for ALAD, glutathione, and/or
metallothionein. The amount of the metallic cation, such as
lead, complexed with each of these polypeptides in the blood
sample can be compared and can be used to determine the
amount and duration of the metallic cation exposure.
A method of the invention can also provide for a determination of whether an animal has been exposed acutely or
chronically to the metallic cation. While not in any way
meant to limit the invention, it is believed that some naturally occurring polypeptides, such as ALAD, bind to the
metallic cation within a short time of exposure (e.g. 3 hours
or less) and other naturally occurring proteins do not bind
the metallic cation until there has been a prolonged exposure
(e.g. at least 24 hours). A comparison of the amount of the
metallic cations bound by these two different types of
polypeptides can indicate whether the exposure is acute or
chronic. A comparison of metallic cation binding by the
acute binding protein and two or more of the chronic binding
protein can indicate whether there has been recent acute
exposure as well as chronic exposure. For example, if
substantiall y all of the metallic cation is detected bound to
a polypeptide that binds the metallic cation within a short
time of exposure, such as ALAD, it is likely that the animal
was acutely exposed. Binding of substantially all of the
metallic cation means preferably binding of about 80-100%
of the total metallic cation detected binding to both types
polypeptides and more preferably about 90-100%.
If the metallic cation is detected bound to several naturally occurring polypeptides, including those polypeptides
that bind the metallic cation after a short and a long
exposure, then it is likely the animal has been chronically
exposed to the metallic cation. For a chronic exposure,
preferably binding to the first type of naturally occurring
polypeptide is about 10-60%, and binding to the second type
of naturally occurring polypeptide is about 20-70% of the
total metallic cation bound to both polypeptides.
The steps of the method include detecting the amount of
the metallic cation bound to a first type of naturally occurring polypeptide, detecting the amount of the metallic cation
bound to one or more second type of naturally occurring
polypeptides and comparing the amount of metallic cation
bound by the first type of polypeptide to the other polypeptides. Preferably the first type of polypeptide is a naturally
occurring polypeptide that binds the metallic cation within a
short period of time after exposure, preferably within about
3-24 hours. The preferred polypeptide that binds the metallie cation after a short period of exposure is ALAD. The
second type of polypeptide is preferably a polypeptide that
binds the metallic cation after a longer duration, preferably
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after at least about 24 hours, and more preferably about
24-72 hours. The preferred polypeptide that binds the metallic cation after a longer exposure is hemoglobin.
The amount of metallic cation bound by a naturally
occurring polypeptide upon an acute exposure (i.e., the first
type) can be compared to the amount of metallic cation
bound by one or more naturally occurring polypeptides that
bind to metallic cations after a chronic exposure (Le., second
type). In a preferred version, the amount of metallic cation
bound to a first type of polypeptide, such as ALAD, is
compared to the amount of metallic cation bound to a second
type of polypeptide, such as hemoglobin.
The amount of metallic cation bound to the polypeptides
can be detected by the immunoassay method of the invention. For example, the amount of a metallic cation such as
lead bound to a first type of naturally occurring polypeptide
can be determined by an immunoassay employing an antibody specific for ALAD as capture antibody and an antibody
specific for lead cation to detect the amount of ALAD lead
complex. The amount of lead bound to ALAD can be
detected by comparison to a standard curve prepared using
known standard as described previously. The amount of
metallic cation such as lead bound to one or more other
naturally occurring polypeptides, such as hemoglobin, can
be determined in a similar manner except that the capture
antibody in this case is an anti-hemoglobin antibody. The
amount of the metallic cation bound preferably is measured
as a percentage of the total amount of metallic cation
detected binding to each of the polypeptides.
The immunoassay method of the invention can be optionally performed in a number of different variations depending
on the specificity of the antibody employed. Some of these
alternate embodiments are described below.
Not all embodiments of the method of the invention
require two antibodies having different specificities. For
example, a method of the invention includes using a single
antibody specific for a naturally occurring polypeptide or
metallic cation-naturally occurring polypeptide complex to
serve as a capture antibody. The capture antibody binds the
naturally occurring proteins that bind the metallic cation
from the sample of body fluid. The naturally occurring
polypeptide in this case is an enzyme whose activity is
inhibited by the binding of the metallic cation. Once the
naturally occurring polypeptide that binds the metallic cation is immobilized by the capture antibody, enzyme activity
is measured. Enzyme activity can be restored by removal of
the metallic cation that inhibits the enzyme activity.
Removal of the metallic cation can be accomplished by
using a chelating agent to bind thc metallic cation or by
adding an excess of the native cofactor or using a combination of both treatments. After removal of the metallic
cation that inhibits enzyme activity, the restored enzyme
activity is measured. The amount of the restored enzyme
activity is an indicator of the amount of the inhibiting
metallic cation bound to the enzyme.
Typically, enzymes that bind to metallic cations and
assays for their activity are known to those of skill in the art.
For example, ALAD is an enzyme that binds to lead cations
and whose activity is inhibited by the binding oflead cations
in place of the native cofactor Zn+ 2 . Tsukamoto et al.,
Biochern. Biophys. ACTA, 570:167 (1979). An antibody
specific for ALAD or lead-ALAD can be used to capture the
ALAD-Pb complexes from the body fluid. The enzyme
activity of ALAD in the Pb-ALAD complexes can be
determined by standard methods as described in Mauzerall
and Granick, J. BioI. Chern., 219:435 (1956). Removal of
the lead cation can be accomplished by incubating the

lead-ALAD in the presence of a chelator such as ethylene
diaminetetraacetic acid followed by an excess of Zn+ 2 ions.
After removal of the lead cations, the restored enzyme
activity can again be measured. The amount of restored
enzyme activity can be used to determine the amount oflead
cation bound to ALAD.
In another alternate version, a method of the invention can
employ a single antibody specific for a naturally occurring
polypeptide that binds at least two metallic cations per
polypeptide. An antibody specific for a naturally occurring
polypeptide that binds at least two metallic cations is first
used as a capture antibody to immobilize the naturally
occurring polypeptide from the sample of body fluid. The
same antibody can then be employed to detect the amount of
the naturally occurring polypeptide that binds at least two of
the metallic cations immobilized. Preferably, the antibody is
specific for (1) the metallic cation or (2) the metallic cation
portion of, or (3) the combination of metallic cation and
coordinate polypeptide portion of the metallic cation-naturally occurring polypeptide complex. For example, an antibody specific for lead cations can be used to capture a
naturally occurring protein that binds at least two lead
cations per polypeptide, such as ALAD. While not in any
way meant to limit the invention, it is believed that the other
lead cation bound to the polypeptide can then be detected.
Once the naturally occurring polypeptide that binds at least
two of the metallic cations per polypeptide is captured or
immobilized, the amount of bound lead cation can be
detected using the same antibody specific for lead cations
but labelled with a detectable agent, as described previously.
These alternate embodiments ofthe immunoassay method
of the invention can also provide for a rapid, low cost
detection of metallic cation contamination in a sample of
body fluid.
D. Immunoassay Kit for Determining the Amount of a
Metallic Cation in a Sample of Body Fluid
The invention also provides kits for detecting one or more
metallic cations in a sample of body fluid. The preferred kit
contains at least two antibodies having different specificities.
One of the antibodies can be a first type antibody while the
other antibody can be a second type antibody. Alternatively
both antibodies can be of the second type as described
above. One of the antibodies in the kit is preferably immobilized on a substrate and the other type of antibody is
preferably labelled with a detectable agent. The antibody
immobilized on the substrate is preferably not labelled with
the detectable agent. The antibody not immobilized on the
substrate is preferably labelled with a detectable agent.
The antibodies are present in the kit in an amount effective
to bind to and detect substantially all of the naturally
occurring polypeptide that binds the metallic cation in the
sample of body fluid.
The preferred antibody specific for a naturally occurring
polypeptide that can bind metallic cation is capable of
binding substantially all of the naturally occurring polypeptide from the sample of body fluid in about 10 minutes or
less. The especially preferred antibody specific for a naturally occurring polypeptide that binds the metallic cation is
an antibody specific for ALAD.
The preferred antibody specific for an epitope (polypeptide portion or combination) on metallic cation-naturally
occurring polypeptide complex or a metallic cation is
capable of detecting concentration of the metallic cation in
a sample of fluid containing at least about 1 Ilg/dl metallic
cation. The especially preferred antibody is an antibody
specific for lead cations.
The kit can contain any number of combinations of the
different types and subtypes of antibodies. For example, the
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kit can contain an antibody specific for a metallic cation and
several different antibodies specific for different naturally
occurring polypeptides that can bind the metallic cation.
Altematively, the kit can contain several different antibodies
specific for different metallic cations and one antibody
specific for a naturally occurring polypeptide that can bind
the metallic cations. Alternatively, the kit can contain a
plurality of antibodies specific for metallic cations and a
plurality of antibodies specific for naturally occurring
polypeptides that can bind the metallic cations. The kit can
also containing a third type of anti-immunoglobulin antibody that is anti-IgG, anti-IgM, or anti-IgA, preferably
labelled with a detectable agent. The preferred kit contains
one monoclonal antibody specific for a naturally occurring
polypeptide that binds the metallic cation and one monoclonal antibody specific for a metallic cation.
Alternatively, the kit can contain a single type of antibody.
For example, the kit can contain an antibody specific for a
metallic cation that can be used to detect the amount of lead
cation bound by a naturally occurring polypeptide that binds
at least two of the metallic cations per polypeptide, as
described previously.
Optionally, the kit can contain a capture antibody specific
for an enzyme that is inhibited by the metallic cation, and
components for measuring the enzyme activity, as described
previously. For example, the kit could provide an antibody
to ALAD, reagents for restoring the enzyme activity such as
EDTA and/or solution containing Zn+2 ions and the reagents
required to measure ALAD enzyme activity such as
O-amino-levulinic acid.
One of the types of antibodies is preferably immobilized
on a solid substrate. Antibodies can be immobilized onto
solid substrates by standard methods, as described in Antibodies: A Laboratory Manual, cited supra. Suitable solid
substrates include materials having a membrane or coating
supported by or attached to sticks, cups, flat packs, or other
solid supports. Other solid substrates include cell culture
plates, ELISA plates, tubes, and polymeric membranes. The
preferred solid substrate is a stick coated with a polymeric
membrane.
One of the types of antibodies is preferably labelled with
a detectable agent, typically the antibody not immobilized
on the substrate. Antibodies can be labelled with detectable
agents by standard methods, as described in Antibodies: A
Laboratory Manual, at pages 319-358, cited supra. Suitable
detectable agents include enzymes, radioactive labels, fluorochromes, and biotin. The preferred detectable agent for
use in the kit is an enzyme, and more preferably, an enzyme
that converts a substrate into a color product that can be
detected visually.
The kit optionally contains means for detecting the detectable agent. Ifthe antibody is labelled with a radioactive label
or a fluorochrome, preferably no means for detecting the
agent is provided in the kit. Typically, the consumer will
have spectrophotometers, scintillation counters, and microscopes that can be used to detect these detectable agents. If
the detectable agent is biotin or an enzyme, means for
detecting the detectable agent can be supplied with the kit.
Suitable examples of means for detecting the detectable
agent include a substrate for the enzyme or avidin. The
means for detecting the detectable agent is present in a
sufficient concentration to detect substantially all of the
second antigen-antibody complex. Preferably, the substrate
for the enzyme is provided in a ratio of about 2: I to 100: 1
with the amount of antibody labelled with enzyme present in
the kit.
The preferred means for detecting the detectable agent is
a substrate that is converted by the enzyme into a colored
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product. The especially preferred combination of detectable
agent and means for detecting the detectable agent is horseradish peroxidase and 2,2'-azino-di-[3-ethyl-benzothiazoline sulfonate] (ABTS).
The kit also optionally contains a lysing agent that functions to lyse cells present in the sample of body fluid.
Suitable lysing agents include surfactants such as Tween-80,
Nonidet P40, and Triton X-IOO. Preferably, the lysing agent
is immobilized onto the solid substrate along with one of the
antibodies.
The kit can also contain a buffer solution for washing of
the substrate between steps. The buffer solution is a physiological solution such as a phosphate buffer, physiological
saline, citrate buffer, or Tris buffer.
The kit can also include standards containing different
concentrations of a metallic cation-naturally occurring
polypeptide complex. The standards can be prepared by
mixing different amounts of the metallic cation ranging from
0.5 Ilgfdl to 50 Ilgldl with a single concentration of a
naturally occurring polypeptide that binds metallic cations.
Solutions containing different amounts of a metallic cationnaturally occurring polypeptide complex are then formed
and run in the immunoassay methods of the invention.
In a preferred version, each of the standard solutions is
contacted with a first type of antibody to form a first
antigen-antibody complex. A second type of antibody
labelled with a detectable agent is then added to form the
second antigen-antibody complex. The amount of second
antigen-antibody complex is detected by measuring the
amount of detectable agent. The amount of the second
antigen-antibody complex is measured for each of the standard solutions and then plotted against the concentration of
the metallic cation initially added to each of the standard
solutions. In addition, the amount of the metallic cation
present in the second antigen-antibody complex can be
measured by atomic absorption spectroscopy and the absolute amount of the metallic cation bound to the naturally
occurring polypeptide can be compared to the amount of
metallic cation initially added and to the amount of the
second antigen-antibody complex determined by detecting
the detectable agent.
Optionally, one or more of the standards containing the
different concentrations of the metallic cation-naturally
occurring polypeptide complex can be immobilized onto a
portion of the solid substrate. Preferably, three different
standards can be immobilized, each in a different portion of
the solid substrate. For example, standards containing a
naturally occurring polypeptide mixed with 1,5 and 10 Ilg/dl
can be immobilized onto the solid substrate by binding to the
immobilized antibody specific for the naturally occurring
polypeptide. A portion of the immobilized solid substrate is
available for binding of the test sample of the body fluid.
When the immunoassay is completed by conversion of the
enzymatic substrate to a colored product, the amount of
colored product produced by the test sample of body fluid
can then be immediately compared with the amount of
colored product produced for each of the standard amounts.
Optionally, the kit can include a card with a visual
representation of the amount of colored product produced by
a particular amount of a standard containing a naturally
occurring polypeptide mixed with a known concentration of
the metallic cation. Preferably, the card contains a plurality
of different visual representations of the different intensities
of colored product associated with the different amounts of
the standard concentrations of the metallic cation. This card
can be used by the consumer to compare the amount of the
colored product produced with the test sample of a body
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fluid and, thereby, quantitate the amount of metallic cation
present in the sample of body fluid.
In a preferred kit, an antibody specific for ALAD is
immobilized onto a portion of a dipstick composed of
membrane attached to a stick. The antibody specific for 5
ALAD is capable of binding substantially all of the ALAD
present in the sample in less than about 10 minutes. The
dipstick also has a lysing agent immobilized along with the
antibody specific for ALAD, preferably Triton X-100. The
preferred kit also contains a phosphate buffer solution and an 10
antibody specific for the lead cation labelled with horseradish peroxidase. The antibody specific for lead cation is
preferably an antibody that can detect lead cation in samples
of body fluids containing as low as about 1 Ilg/dl of lead
cation. The preferred kit also contains a substrate for horse- 15
radish peroxidase, preferably ABTS. The preferred kit also
contains a card with a plurality of visual representations of
different amounts of colored product formed by conversion
of ABTS by horseradish peroxidase for different standard
amounts of samples containing the metallic cation.
20
EXAMPLE I
Preparation of Monoclonal Antibodies Binding to a
Metallic Cation Mercury
The strategy for both inducing and selecting metal cationspecific antibodies was to prepare a complex in which the
metal ion could be bound as a monodentate ligand. The
coordination number of most metals, which denotes the
number of ligands attached to the central metal atom in a
complex, is generally four to six, although numbers from
three to ten have been noted. (D. Craig et al., Chelating
Agents and Metal Chelates, F. Dwyer and D. Mullon editors,
pp. 51-93, Academic Press, NY (1966).) In the complex
used in these experiments, mercuric chloride was added to
glutathione (GSH), which is a tripeptide of L-y-glutamylcysteinylglycine. The disassociation constant of mercuric
ions bound to sulfhydryl groups has been reported to be as
high as 1O-42M. Thus, the interaction is sufficiently strong
that a stable complex can be formed by interaction of
mercury with only the sulfhydryl group of cysteine, without
requiring the participation of either the amino or carboxyl
groups of the other two amino acids. (B. Fuhr et al., 1. Am.
Chern. Soc., 95:6944 (1973).)
The immunogen consisted of GSH-HgCl conjugated to a
carrier protein keyhole limpet hemocyanin. BALB/c mice
were given mUltiple intraperitoneal injections of the HgCIGSH-keyhole limpet hemocyanin emulsified in Freund's
adjuvant, with a total of 50 Ilg of protein per injection. The
mice were bled after the fifth injection, and their sera were
analyzed by ELISA against bovine serum albumin (BSA)GSH and BSA-GSH-HgCl for evidence of mercury-specific
antibodies. The results are shown in Table 1 below.
TABLE 1
Reactivity of Serum from
BALB/c Mice Injected with BSA-glutathione-HgCl
Mouse #

BSA-GSH

BSA-GSH-HgCl

% Difference

1
2
3
4
5
6
7

1.332
0.808
2.382
0.654
0.682
0.453
0.567

1.214
0.886
1.505
0.947
0.848
0.756
0.865

-8.9
+9.7
-36.8
+44.8
+24.3
+66.9
+52.6
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TABLE I-continued
Reactivity of Serum from
BALB/c Mice Injected with BSA-glutathione-HgCl
Mouse #

BSA-GSH

BSA-GSH-HgCl

% Difference

1.670
1.456
-12.8
8
0.299
0.308
background
+3.0
One hundred microliters of serum was added to the
wells of microtiter plates to which either BSA-glutathione
or BSA-glutathione-HgCl had been adsorbed. After
incubation for 2 hours at room temperature, the plate was
washed three times with PBS followed by addition of 100 ;U
of goat anti-mouse serum. The plate was incubated and
washed as above, then 100 ;U of rabbit anti-goat serum
conjugated with alkaline phosphatase was added. After
incubation and washing as above, 100 ;U of 2 mM paranitrophenyl phosphate in 1M diethanolarnine, pH-9.6,
containing 25 mM MgC12 , was added, and the A405 of each well
was measured after incubation at room temperature of 15-30
minutes. Percent difference was calculated by the
following formula:
Percent difference = I(A405 of BSA-GSH-Hg - A405 of
BSA-GSH) + (A405 of BSA-GSH)] x 100.
Serum from an unimmunized mouse served as background
reactivity for each antigen.

The initial screening for the presence of mercury-specific
antibodies in serum was simply higher reactivity with the
immunogen containing mercury than with immunogen not
containing mercury. Several mice, (e.g., #'s 2, 4,5,6, and 7)
satisfied this condition.
Mouse #6 was given a booster injection, and its spleen
was used for fusion three days later. The ELISA procedure
used to screen the hybridoma culture fluids was the same as
described in the legend to Table 1.

35

TABLE 2
Reactivity of Hybridoma Antibodies with
BSA-glutathione-HgCl and BSA-glutathione

40

Hybridoma
IHll

2A9

45

3A12
3H9
IFIO
3E8
4AlO
Neg. control

BSA-GSH-HgCI

BSA-GSH

1.246
0.758
1.792
1.606
1.175
1.076

1.202
1.052
2.217
2.134
0.406
0.410
0.400
0.456

1.104
0.428

Of 134 hybridomas obtained, seven of them demonstrated
reactivity consistent with specificity for some part of the
GSH-HgCI component of the immunogen (Table 2). MAb's
1Hll, 2A9, 3A12, and 3H9 showed a pattern consistent with
GSH-specificity, since they reacted with GSH whether
HgCI2 was present or not. On the other hand, MAb's 1FlO,
55 3E8, and 4AlO were two- to three-fold above background
when assayed with BSA-GSH-HgCI. Background was
established for both BSA-GSH and BSA-GSH-HgCI by
measuring their reactivities with a dinitrophenol-specific
monoclonal antibody.
60
These results suggested that the latter three antibodies
(IFlO, 3E8, and 4AlO) were specific for either mercuric ions
alone or for an epitope consisting of both GSH and HgCI 2.
Mab's 4AlO (BN No. 4A10B4, ATCC No. HB 10381) and
1FlO were subcloned and analyzed further to determine
65 whether they would react with mercuric chloride by itself.
To do so, an inhibition assay was performed in which tenfold
dilutions of HgCl 2 from 1O-2M to lO- 11 M were used to
50
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sample containing the following mixture of metals: 0.2 mg/L
Hg++, 100 mg/L Ba++, 1 mg/L Cd++, 5 mg/L Cr+++, 5 mg/L
Pb++, and 5 mg/L Ag+. The sample was diluted to known
Hg++ concentrations, which were then assayed by ELISA
5 and compared to results obtained with a standard consisting
of known concentrations of mercury chloride.
Briefly, the ELISA was conducted as follows. The QC
sample and HgCl 2 were diluted in water to mercury con10 centrations ranging from 0.5 to 200 ppb, then analyzed by
ELISA. A sample containing the same concentration of all
other metals as the QC sample except mercury was also
included. The absorbance obtained in analysis of both water
without added mercury and the EPA sample without mercury
15 was 0.263. Each point represents the average absorbance
Percent inhibiton = (1 - {[A405 of expo - A405 of neg] .,.
obtained from quadruplicate analyses of each sample. See
FIG. 2.
[A405 of pos. - A405 of neg.]}) x 100
The results in FIG. 2 show that significant reactivity was
The results are shown in FIG. 1.
obtained with both the EPA sample and the mercury standard
The binding of both antibodies to adsorbed antigen was 20 at 2 ppb mercury, and the absorbance for both samples was
inhibited by soluble HgCI 2 , with 50% inhibition between
linear up to 20 ppb mercury. Reactivity was due to the
1O-9 M and lO-lOM HgCl 2 for each. The specificity of the
presence of mercury and not to recognition of one of the
inhibition was demonstrated by the inability of the same
other metals, since a sample containing all of the metals
concentrations of mercuric chloride to inhibit the binding of
except mercury in the same concentrations as in the EPA
an asparagine synthetase-specific monoclonal antibody
25 sample gave the same absorbance as water containing no
(MAb 3Dll) to asparagine synthetase. These data demonmercury.
strated that reactivity of both antibodies with HgCl 2 was
The results in FIG. 2 clearly demonstrated that the ELISA
independent of the presence of either GSH or KLH.
was capable of sensitive and reproducible detection of
mercuric ions in water, but they did not reveal how well the
EXAMPLE II
30
ELISA correlated with atomic absorption. This is an important consideration since cold-vapor atomic absorption is
Characterization of the Binding Characteristics of
currently the method of choice for mercury determination.
Monoclonal Antibodies to Mercury
To correlate the results obtained from the two methods, an
Clearly, antibodies capable of reacting with soluble mer- 35 atomic absorption mercury reference standard was diluted in
curic chloride were identified. It was of interest, then, to
O.IM HEPES, pH 6.8, to a mercury concentration of 100
determine the affinity of the antibodies for mercuric ions, as
ppb. At this point, two aliquots were removed and diluted to
well as to identify other metals to which they might bind.
the appropriate concentrations for immunoassay in HEPES
The other metal salts used for these analyses included
or for atomic absorption in 10% nitric acid. Samples conbarium chloride, cadmium chloride, chromic chloride, cop- 40 taining 0, 2, 4, 5, 10 and 15 ppb mercury were then analyzed
per chloride, ferrous sulfate, gold chloride, mercuric acetate,
by both methods. The values shown represent the mean and
nickel chloride, selenium oxide, silver chloride, and zinc
one standard deviation of quadruplicate analyses by immuchloride. The procedure used to determine the affinity of the
noassay and triplicate analyses by atomic absorption. (See
antibodies for the various metals was the competition ELISA
FIG. 3.)
described by Friguet et al. (J. Immunol. Methods, 77:305
As shown in FIG. 3, the results obtained from the two
45
(1985), which is hereby incorporated by reference.
methods were in close agreement, as indicated by a correThe results indicated that the disassociation constant of
lation coefficient of >0.99. In addition, the standard deviaMAb 4AIO for HgCl 2 was 2.3±0.8xlO-9 M, while that of
tion of the immunoassay at most mercury concentrations
MAb IFIO was 3.7±1.5xlO-9 M. Neither antibody bound
was the same or less than that obtained by atomic absorpany of the other metals to a detectable extent. However, both 50 tion. These results indicated that, under the conditions of this
antibodies did have a similar affinity for mercuric acetate,
assay, quantitation of mercury by ELISA was as precise as
with the affinities being 4.l±O.lxlO-9 M and 8.2±2.5xlO-9 M
cold-vapor atomic absorption.
for 4Al 0 and IFIO, respectively. These results indicated that
the mercuric ion itself was the major epitope recognized by
these antibodies, regardless of the counterion originally 55
EXAMPLE III
present in the mercury-containing compound being assayed
for antibody reactivity.
Equilibrium dialysis of these monoclonal antibodies with
Production of Monoclonal Antibodies to a Lead
uncomplexed glutathione was conducted and it was deterCation
mined that the disassociation constant for glutathione was 60
5
less than 1O- M. This data further supports the view that
The same strategy used for production of mercury-spethese antibodies are immunoreactive with a bare metal
cific antibodies employing immunization of mice with a
cation.
metal cation-spacer arm carrier has now been applied to
The specificity of the antibodies was further illustrated by
generation of antibodies specific for lead. Initially, seven
their ability to detect mercury at concentrations in the 65 antibodies were identified that reacted with a carrier protein
part-per-billion range, even in the presence of other metals.
only when lead was present. The ELISA results obtained
This was demonstrated with an EPA Quality Control (QC)
from screening these antibodies are shown below.

inhibit antibody binding to BSA-GSH-HgCl adsorbed to a
micro titer plate.
The inhibition assay was conducted as follows. Fifty
microliters of each concentration of mercuric chloride and
50 fll of diluted ascites fluid containing the indicated antibody were incubated for 30 minutes at room temperature in
the wells of a microtiter plate containing adsorbed BSAglutathione-HgCI. The plates were then washed, and horseradish peroxidase-conjugated goat anti-mouse serum was
added. After incubation and washing as above, ABTS substrate was added, and the A405 was measured after 15
minutes. Each point represents the average of triplicate
determinations. Percent inhibition was calculated according
to the fonowing formula:
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Hybridoma
6Bll
8E7
4E8
3B8
9D3
3B7
lC3

26

BSA-GSH

BSA-GSH-Pb

0.298
0.055
0.195
0.212
0.191
0.074
0.161

0.954
0.987
0.618,
0.975
0.584
0.710
1.560

Hybridoma
14Fll
5
lC3

10

Several of these antibodies have been assayed for detection
of lead bound to other carriers, such as other globular
proteins like ovalbumin, or synthetic polypeptides such as
poly-L-Iysine.
A monoclonal antibody specific for lead cation can have
a disassociation constant for lead cation of less than 1O-9 M
and does not appreciably bind to cadmium, copper, zinc,
mercury, nickel, and cobalt cations to any appreciable
extent.
To determine whether any of these antibodies would bind
lead in solution, mAb's lC3 and 14Fll (prepared as
described in Example IV) were used in competition assays
as described in Example I, to see if lead nitrate in solution
would inhibit the binding of either mAb to BSA-GSH-Pb++
adsorbed to a solid phase. Briefly, 50 J.!l of each concentration of lead acetate and 50 J.!l of diluted ascites fluid
containing the indicated antibody were incubated for 30
minutes at room temperature in the wells of a microtiter
plate containing adsorbed BSA-glutathione-Iead acetate.
The plates were then washed, and horseradish peroxidaseconjugated goat anti-mouse serum was added. After incubation and washing as above, ABTS substrate was added,
and the A405 was measured after 15 minutes. Each point
represents the average of quadruplicate determinations. Percent inhibition was determined according to the formula in
the legend to FIG. 1. The results are shown in FIG. 4.
The binding of both IC3 and 14Fl1 is inhibited by soluble
lead acetate at concentrations ranging from 10 to 100 ppm,
with 50% inhibition at approximately 20 ppm and 150 ppm
for mAb's lC3 and 14Fll, respectively. Thus, these two
antibodies, in addition to reacting with lead attached to a
carrier, also react with lead in solution.
EXAMPLE IV
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20

25

ALAD-Pb

ALAD

0.751
1.813
1.586

0.050
0.048
0.030

These antibodies are specific for an epitope on the ALADlead complex and do not react with epitopes on ALAD
alone.
The results shown above clearly demonstrate that the
same condition that was found for mercury also exists for
lead, namely that antibodies can be produced that recognize
lead when it is either in solution or attached to a carrier.
Monoclonal antibody 14Fll could detect lead in solution at
10 ppm and 1C3 could detect lead at 1 ppm. Monoclonal
antibodies reactive with ALAD bound to lead and noncrossreactive with ALAD alone can be used in an assay to
detect the amount of lead present in a blood sample.
The immunoreactivity of monoclonal antibodies 14Fll
and I C3 with bovine ALAD complexed to other metal
cation was also tes.ted. Bovine ALAD was incubated with 1
mM of metal cations including Pb, Zn, Cu, Cd, Ni, and Hg,
for 60 minutes. The bovine-ALAD metal complexes were
then placed in an ELISA well and assayed for the abilityto
bind monoclonal antibodies 14Fll and lC3. The results are
shown below.
Metal Ion

l4Fll

Pb+2

0.638
0.060
0.076
0.908
0.102
0.070
0.135
0.126
0.590
0.128

30
Zn+2

Control
Pb+2
Cu+2

35

Control
Cd+2
Ni+2

Hg+2
Control
40

Metal Ion

lC3

Pb+2
Hg+2
Cd+2
Control

0.413
0.150
0.064
0.064
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EXAMPLE V
Preparation of Monoclonal Antibodies Specific for
Pb-ALAD
Monoclonal antibodies specific for Pb-ALAD were prepared by standard methods. The amount of ALAD complexed with Pb is a sensitive indicator of the toxicity of the
lead contamination. ALAD is a naturally occurring enzyme
whose activity is inhibited by lead contamination and this
inhibition represents one of the toxic effects of lead contamination. The amount of Pb-ALAD present in the blood
sample is a good indicator of the toxicity level associated
with the lead contamination of the patient.
A monoclonal antibody to Pb-ALAD was prepared as
described in Example 1. The resulting hybridomas were
screened for immunoreactivity with Pb-ALAD and ALAD.
A monoclonal antibody, designated 14Fll, has been produced by injection of Pb-ALAD. The ELISA results when
this antibody and antibody IC3 (prepared as described in
Example III) were tested with ALAD-Pb and ALAD alone
are shown below:

50

55

60

65

Production of Hybridoma Antibodies Specific for
ALAD
Since ALAD is one of the earliest and most sensitive
indicators of exposure to lead, it is a logical target for
determination of the lead burden in an individual. ALAD is
a large, multimeric protein, so it will induce formation of
high affinity, specific monoclonal antibodies. The ALADspecific antibody can be used to capture the enzyme from a
sample of body fluid for subsequent detection oflead bound
to it.
The injection regimen for production of antibodies specific for ALAD was as follows. Bovine liver ALAD was
mixed with adjuvant and injected intraperitoneally into
BALB/c mice. Each mouse was given three injections with
50 flg of ALAD per injection. The presence of ALADspecific antibodies was monitored by an ELISA in which
200 J.!l of ALAD at a concentration of 5 flg/ml is adsorbed
to the wells of 96-well polystyrene microtiter plates by
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incubation at room temperature for 2 hours. Two hundred
microliters of 1% polyvinyl alcohol in PBS was added to
each well and incubated at room temperature for one hour to
block the nonspecific protein-binding sites. Fourfold dilutions of each serum sample were prepared, and 100 J.!l of
each was added to duplicate wells of a microtiter plate. After
incubation at room temperature for 60 minutes, the plates
were washed three times with ELISA wash (PBS with 0.1 %
Nonidet P-40). One hundred microliters of goat anti-mouse
serum conjugated to horseradish peroxidase was added, and
the plates were incubated and washed as above. Peroxidase
substrate (ABTS) was then added, and the absorbance of
each well at 405 nm was measured after incubation for 15
minutes at room temperature. Controls consist of assaying
each serum dilution against bovine serum albumin instead of
ALAD to determine their nonspecific reactivity, and assaying serum from a non-injected mouse against ALAD. Three
mice injected as described above show an ELISA titer of
>10,000 against ALAD and <1,000 against BSA.
The spleen from one of these mice was used for fusion
with SP2IO myeloma cells for production of hybridomas,
according to standard methodology, as described by J.
Liddell et al., in A Practical Guide to Monoclonal Antibodies, pp. 67-88 (1992). Four monoclonal antibodies were
obtained from the fusion. The ELISA results from initial
screening of these antibodies against ALAD and BSA-GSH
are shown below. BSA-GSH was included to identify
polyreactive antibodies.
Hybridoma

ALAD

BSA-GSH

SIN'

lC6
IOG4
llB12
12F8

1.466
0.796
1.938
1.417

0.128
0.109
0.213
0.131

11.5
7.3
9.1
10.8

Hybridoma
llB12

ALAD-Pb

0.877

0.666
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These results demonstrate that mAb llB12 reacted with
ALAD regardless of the presence of lead.
To assay for antibody binding to human erythrocyte
ALAD, inhibition of the enzyme activity in the presence of
the monoclonal antibody was measured. The appropriate
amount of each antibody was pre-determined by titration in
a solid-phase ELISA and added to the wells of a microliter
plate. After antibody adsorption to the plate, 100 J.!l of a
lysate from washed human erythrocytes was added. The
plates were incubated at room temperature for 30 minutes,
washed, and ALAD activity was determined by a modification of the procedure of Tsukamoto et al., BBA,
570: 167-168 (1979). Briefly, 100 J.!l of Tris-acetate, pH 7.1,
containing 4 mM o-aminolevulinic acid hydrochloride was
added and the plates were incubated at 37° C. for various
times. At the appropriate time, 100 J.!l of Ehrlich's reagent
was added, and the reaction mixture was incubated for 30
minutes at room temperature to allow for color development. The absorbance at 540 nm was then determined to
measure porphobilinogen synthesis. The results obtained
after incubation of the reaction mixture for 48 hours are
shown below.
Hybridoma
llB12

Enzyme

Substrate

A450

+
+

+

2.066
.065
.026
.027

+

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 35
'SIN = Signal· to-Noise Ratio. This was obtained by dividing the adsorhance
with ALAD by that obtained from assay against BSA-GSH.

The results shown above indicate that these four antibodies were specific for ALAD, as indicated by their preferential
reactivity with the specific antigen (ALAD) over a nonspecific one (BSA-GSH). However, the ALAD-specific antibodies were induced by injection of bovine liver ALAD and
were identified by reactivity with the same immunogen
adsorbed to the wells of a microtiter plate. It was possible,
then, that the antibodies were specific for a species-specific
epitope accessible only when ALAD was adsorbed to a
microtiter plate. Adsorption of proteins to a solid support can
cause denaturation, so that any monoclonal antibody
detected in this assay might be specific for a denatured
epitope and would not react with the native enzyme. In
addition to recognizing native ALAD in an erythrocyte
lysate, an ALAD-specific antibody preferably fulfilled two
additional requirements: first, it had to recognize an ALAD
epitope whose ability to react with the antibody would not
be influenced by the presence of lead; and, second, it had to
bind a sufficient amount of ALAD to allow immunological
detection of any attached lead. The ability of each of the
ALAD-specific antibodies shown above to fulfill these
requirements was examined.
To determine whether any of the antibodies would bind
ALAD with lead attached, ALAD was adsorbed to the wells,
after which Pb was added to some wells but not to others.
MAb I1BI2 was then tested for reactivity withALAD in the
presence and absence of lead. This antibody was selected
because it consistently reacted more strongly with ALAD in
routine ELISA's than the other antibodies. The results are
shown below.

ALAD

40

45

The numbers represent the absorbance at 540 nm in the
experimental samples, which contained the reaction mixture
described above. The controls consisted of the absorbance at
540 nm obtained with a sample incubated for the same
length of time in the absence of monoclonal antibody, or in
the absence of enzyme, or in the absence of substrate. The
results indicated that llB12 was suited for trapping enzymatically active ALAD in human erythrocyte Iysates.
Monoclonal antibodies that react only with lead-ALAD,
as described in Example IV, and not with ALAD can also be
selected and used to provide for greater sensitivity.
EXAMPLE VI
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Development of an Immunoassay for the Detection
of Metallic Cation in a Sample of Body Fluid
A method for detecting a metallic cation in a sample of
body fluid was developed by detecting the amount of the
metallic cation bound to a naturally occurring protein such
as ALAD present in the sample of body fluid. Two antibodies specific for ALAD, prepared as described in Example IV,
were used to determine whether lead could be detected in
blood samples in the assay design envisioned for the kit
format. The blood samples used for this experiment were
bovine blood samples from cattle exposed to lead, which
were obtained from the Center for Disease Control.
MAb llB12 (ALAD-specific) was adsorbed to the weJls
of a microtiter plated as described above. One hundred
microliters of extract containing ALAD from two blood
samples from cows exposed to lead. The two samples were
designated BES90, which contained lead at 8.5 Ilg/dl and
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BE890, which contained lead at a concentration of 15 flg/dl.
After incubation for 30 minutes in the well, the extract was
removed, the plates were washed, and 100 f.1l of a I: 1000
dilution of ascites fluid containing mAb 14Fll (lead-specific) or IOG4 (ALAD-specific) was added. After incubation
for 60 minutes, a peroxidase labelled anti-IgM antibody was
added to each well. After incubation and washing as above,
100 f.1l of ABTS was added, and the absorbance of 405 nm
was measured. The results are shown below.

5

10

Blood Sample
PBS
BE590
BE890

1004
Absorbance

14Fll
Absorbance

0.195
1.452
1.451

1.091
1.195
1.405

The numbers represent the absorbance at 405 nm of the
samples in the ELISA done as described above. The sample
designated as PBS served as a negative control and contained only PBS instead of extract from a blood sample.
As can be seen, Pb was detected in the contaminated
samples using the immunoassay in accordance with the
invention. These results are extremely important because
they indicate that the approach described for detecting lead
bound to ALAD will do so in a "real world" blood sample.
In spite of the seeming lack of sensitivity of mAb 14Fll for
binding to soluble lead (FIG. 4), it is sufficiently sensitive to
be used for detecting lead bound to ALAD. As previously
mentioned, it could be that, since this mAb was induced by
Pb-ALAD, it will react with soluble lead, but preferably
reacts with lead bound to ALAD.

EXAMPLE VII

Detecting Lead Bound to Hemoglobin

Sample

Adsorbance

Blood-Pb

I
2
3
IX PBS

1.291
0.225
0.244
0.093

55
4
2
0

There is a good positive correlation between adsorbance
and blood-lead values. Thus, immunoassays for lead bound
to hemoglobin can be used as an indication of a patient's
lead burden.
EXAMPLE VIII
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Detecting Lead Bound to Serum Albumin
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Lead binds to many of the proteins found in blood cells
and plasma. Serum albumin, a major constituent of serum,
is one of the proteins that also binds lead. An immunoassay
that uses antibodies to serum albumin and antibodies to lead
can specifically detect lead bound to serum albumin.
Antibodies to serum albumin are generated easily using
standard laboratory animals, and also are available commercially. These antibodies may be polyclonal or monoclonal,
and can be very specific, e.g. for rare variants or for specific
epitopes or for one species, or can be less specific and more
crossreactive. Antibodies to lead have been generated as
described in Example III.
Immunoassays to detect lead bound to serum albumin
have been done. First, antibodies to serum albumin (Sigma
Chemical Co., St. Louis, Mo.) were adsorbed to a solid
substrate. Next, agents to block non-specific adsorption were
incubated on the solid substrate. Third, samples of lead
contaminated human serum were incubated on the solid
substrate. Fourth, a monoclonal antibody specific for lead
(l4Fll) was incubated on the solid substrate. This was
followed by incubation with an antibody reporter enzyme
conjugated antibodies that bind to the lead antibodies conjugated to a reporter enzyme, and then followed by a
chromogenic enzyme substrate.
The results show that lead bound to serum albumin was
detected in an immunoassay using two different antibodies
as described in Example VI.

Lead binds to many of the proteins found in blood cells
40
and plasma. Hemoglobin, a major constituent of erythrocytes, is one of the proteins that binds lead. Gercken et al.,
Anal. Chern., 63:283-287 (1991). An immunoassay that uses
antibodies to hemoglobin and antibodies to lead might
specifically detect lead or mercury bound to hemoglobin.
45
Antibodies to hemoglobin are generated easily using
Sample
Adsorbance
Blood-Pb
standard laboratory animals, and also are available commercially. These antibodies may be polyclonal or monoclonal,
I
1.251
35
and can be very specific, e.g. for rare variants or for specific
2
0.390
20
subunits or for one species, or can be less specific and more 50
3
0.442
16
12
4
0.400
crossreactive. Antibodies to lead have also been generated as
0.352
4
5
described in Example III.
IX PBS
0.093
0
Immunoassays to detect lead bound to hemoglobin have
been done. First, monoclonal antibodies to hemoglobin
This immunoassay is useful to qualitatively screen for the
(obtained from Medix Biotech, Inc.) were adsorbed to a
55 presence or absence of Pb contamination of a blood sample.
solid substrate. Next, agents to block non-specific adsorption
were incubated on the solid substrate. Third, samples of
EXAMPLE IX
lysed erythrocytes from lead contaminated human blood
were incubated on the solid substrate. Fourth, a monoclonal
Comparison of an Acute vs. Chronic Lead
antibody specific for lead (l4FII) was incubated on the solid 60
Exposure
on the Detection of Pb Bound to ALAD
substrate. This was followed by a reporter enzyme conjuand Hemoglobin
gated with a chromogenic enzyme substrate. The amount of
lead present in the original sample should positively correNaturally occurring proteins that bind to lead can also
late with the amount of color produced.
serve as indicators of an acute vs. chronic exposure to lead.
The results show that lead bound to hemoglobin was 65 For example, it is known that inhibition of ALAD activity
with Pb+2 after a single exposure in mice occurs as early as
detected using an immunoassay employing two different
3 hours and peaks in 24 hours and then the ALAD activity
antibodies as described in Example VI:
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returns to normal activity within 2-4 days post-exposure.
Schlick et aI., Areh. Toxieol., 43 :213 (1980).Binding of Pb+2
to hemoglobin may proceed more slowly and Pb may be
retained by hemoglobin for a longer period of time. An
immunoassay employing a comparison of lead bound to 5
ALAD and to hemoglobin may allow diagnosis of an acute
vs. chronic exposure to Pb+2 .
Rabbits will be exposed to an acute and chronic Pb
exposure in their drinking water and Pb concentration bound
to ALAD and hemoglobin determined over time. Lead 10
acetate will be administered to the animals in water bottles.
Sodium acetate will be fed to control animals. The treatment
groups will be as follows:
Treatment 1 (2 to 4 rabbits)
Treatment with 10 mg Pb/kg/day for 5 days, followed by 15
control treatment for 5 weeks.
Treatment 2 (2 to 4 rabbits)
Control treatment for 5 weeks followed by 5 days of 10
mg Pb/kg/day.
20
Treatment 3 (2 to 4 rabbits)
Treatment of rabbits with 1 mg Pb/kg/day for 6 weeks.
Treatment 4 (2 to 4 rabbits)
Control treatment for 6 weeks.
Blood samples will be taken on the first day of treatment
every 3 hours and analyzed for Pb bound to ALAD, as 25
described in Example VI, and for Pb bound to hemoglobin,
as described in Example VII. Thereafter blood samples will
be taken regularly, typically once a week or less, and
analyzed similarly. It is likely that the ratio of the amount of
Pb detected bound to ALAD compared to the amount bound 30
to hemoglobin after an acute exposure will be higher than
the ratio of the amount of Pb detected bound to ALAD
compared to the amount bound to hemoglobin after a
chronic exposure. It is expected that the amount of lead
bound to ALAD will be higher than the amount of lead 35
bound to hemoglobin after an acute exposure. It is expected
that the amount of lead bound to ALAD will decrease over
time in a chronic exposure as compared to an acute exposure.
40

EXAMPLE X
Method for Identifying Naturally Occurring
Polypeptides That Bind Metallic Cations

45

Naturally occurring polypeptides beside ALAD are
capable of binding to metallic cations and can be used to
detect the presence of and/or to quantitative the amount of
a metallic cation in a body fluid. A method for identifying
other naturally occurring polypeptides that bind to metallic 50
cations and/or to identify whether the polypeptides bind
metallic cations at a low enough concentration to be a
sensitive indicator of metallic cation contamination includes
using a Western blot technique. The Western blot technique
is carricd out according to standard methods, as described in 55
Antibodies: A Laboratory Manual, Harlow & Lane, editors,
Cold Spring Harbor, Cold Spring, N.Y. at pages 571-610
(1988).
First, blood samples not thought to be heavily contaminated with exogenous metallic cations, such as lead "or 60
mercury or methylmercury, were treated with a lysing agent
such as Triton X-IOO. The lysing agent acts to lyse cells,
including red cells present in the blood sample. The samples
run on Western blots had known concentrations of blood
lead determined by anodic stripping voltametry ranging 65
from 4 flgldl to 55 flg/dl. The samples were then mixed with
4 X sample buffer of 76.0 mg Tris base, 2 gm SDS (sodium

dodecylsulfate), 10 ml glycerol, 5 ml ~-mercaptoethanol,
and distilled H20 to 25 mls (pH=6.8). Each sample contained a metal containing red cell lysate (varying amounts),
10 fll of 4 X sample buffer and 40 f.1l distilled H2 0. The
samples were mixed vigorously and boiled for 5 minutes.
Samples were loaded onto Tris/glycine SDS polyacrylamide
gels and the gels were electrophoresed under standard
conditions as described in Antibodies: A Laboratory
Manual, cited supra.
Once electrophoresis was completed, the proteins in the
samples were transferred to nitrocellulose membranes by
either simple diffusion, vacuum assisted solvent flow, or
electrophoretic elution. The preferred method is electrophoretic elution by semi-dry transfer. With the semi-dry
transfer method, the gel nitrocellulose membrane sandwich
was placed between absorbent paper soaked in transfer
buffer. The transfer buffer contained 48 mM ofTris base, 2M
glycine, 3% methanol, and distilled water. On the bottom
plate of the gel transfer apparatus (the anode), the sandwich
for electroelution was assembled as follows: a sponge, 3
layers of absorbent paper soaked in transfer buffer, the
polyacrylamide gel wetted with H 2 0, nitrocellulose membrane soaked in water, and 3 layers of absorbent paper
soaked in transfer buffer, sponge, and the upper electrode
(cathode) on top of the stack. The electrodes were connected
and current was applied for 40 minutes at 100 V.
Once transferred to the nitrocellulose membrane, the
proteins were reacted with specific antibodies. Before the
membrane was treated with the antibodies, however, nonspecific binding of the antibody was blocked by treating the
membrane with a protein or detergent solution, such as
non-fat dry milk. The membranes were then incubated with
monoclonal antibodies specific for the metallic cations.
Each membrane was removed from the blocking solution
and washed twice for 30 minutes each in PBS. The monoclonal antibody 14FII specific for lead was incubated with
each of the membranes in 1% polyvinyl acetate, 5% bovine
calf serum, 0.01% sodium azide in phosphate buffered saline
in a shallow tray. Antibody concentration should be between
1-50 flg/ml. The membranes were incubated for at least 2
hours at room temperature with agitation. After incubation,
the membrane is washed twice with PBS and twice with
ELISA wash (PBS with 0.1 % Tritonx-100).
The membrane was then treated with a enzyme labelled
secondary antibody. The secondary antibody is a goat antimouse IgM antibody labelled with horseradish peroxidase.
The membrane and the secondary antibody were incubated
for 1.5 hours at room temperature with agitation. The gel
was then rinsed twice for 30 minutes with PBS and twice for
30 minutes with ELISA wash. To develop the membrane, the
membrane was incubated with the peroxidase substrate TM
Blue (TSI, Inc.).
The results are shown in FIG. 5. Lead bound to hemoglobin was detected as shown in Lanes 3, 4 and 5 in blood
samples containing as low as 5 flg Pb/dl. The hemoglobin
band is seen at 64,000 daltons. Other bands visualized
represent carbonic anhydrase (29,000), albumin (66,000),
transferrins (76,000-81,000), and hemocyanin (70,000).
Lane 2 represents a Western blot of a lead depleted red cell
lysate sample. These results show that naturally occurring
metallic cation containing proteins can be readily identified
using the metallic cation specific antibodies of the invention
and Western blot.
Bands identified by Western blot can be identified by their
molecular weights, and these bands can be eluted from
companion gels for further characterization and identifica-
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tion by methods known to those of skill in the art. For
example, a naturally occuning polypeptide binding metallic
cations can be identified by using monoclonal antibodies
specific for known blood polypeptides. Membranes run
under the same conditions can be incubated with monoclonal antibodies specific for human serum albumin or
hemoglobin or other known blood proteins.
By comparing the Western blot results for blood samples
mixed with different concentrations of the metallic cations,
those polypeptides detected as binding lead or mercury at
very low concentrations (less than about 25 Ilg!dl) can be
considered sensitive enough to use in a immunoassay for
metallic cations. It can also be determined if the binding of
the metallic cation by the polypeptide is related linearly to
the amount of metallic cation initially added to the sample.

34

readily apparent to those skilled in the art, and this application is intended to cover any adaptations or variations
thereof.
What is claimed is:
1. A method for detecting a metallic cation in a sample of
5
a body fluid of an animal, which comprises:
contacting an effective amount of a first antibody specific
for a naturally occuning polypeptide or a functional
portion of the polypeptide with the sample of body fluid
containing the metallic cation to form a first antigen10
antibody complex, wherein the naturally occurring
polypeptide can bind the metallic cation;
adding an effective amount of a second antibody specific
for the metallic cation to the first antigen-antibody
15
complex to form a second antigen-antibody complex;
and
determining the amount of the metallic cation in the
EXAMPLE XI
sample of the body fluid by detecting the amount of the
second
antigen-antibody complex.
Formation of Monoclonal Antibodies to Glutathione
20
2. A method according to claim 1, wherein the second
or Glutathione Metallic Cation Complex
antibody specific for the metallic cation is a monoclonal
Monoclonal antibodies specific for glutathione or gluantibody specific for metallic cation is selected from the
tathione-mercury complex were obtained by following the
group consisting of transition metals, Group IlIa metal!
immunization procedure described in Example I. As shown
metalloids, and Group IVa metal/metalloids.
3. The method according to claim 2, wherein the metallic
in Table 2 on page 35, monoclonal antibodies reactive with 25
both glutathione HgCI and glutathione complexed to the
cation is lead.
carrier bovine serum albumin were isolated and identified in
4. A method according to claim 1, wherein the second
antibody specific for the metallic cation does not substanan ELISA assay. Monoclonal antibodies IHll, 2A9 was
tially cross-react with other metallic cations.
specific for both BAS-GSH-HgCI and BSA-GSH. Mono5. A method according to claim 1, wherein the second
clonal antibodies 3AI2 and 3H9 bound to BSA-GSH pref- 30
antibody specific for the metallic cation has a dissociation
erentially, rather than to the BAS-GSH-HgCI. The monoconstant of about 10-4 to 10-13 .
clonal antibodies can be further characterized to ensure that
6. A method according to claim 1, wherein the second
they are specific for the glutathione-mercury complex or
antibody specific for the metallic cation is labelled with an
glutathione and not for epitopes on BSA.
Monoclonal antibodies IHII and 2A9, 3AI2 and 3H9 can 35 enzyme.
7. A method for determining whether an animal has been
be assayed in an ELISA for the ability to bind to glutathione
exposed acutely or chronically to a metallic cation, which
alone or glutathione-mercury complex. Briefly, glutathione
comprises:
or glutathione mercury complex can be incubated in the
detecting the amount of the metallic cation bound to a first
wells of an ELISA plate under conditions that allow the 40
glutathione or glutathione complex to bind to the plate. The
type of naturally occuning polypeptide that binds the
ELISA plate is then washed and incubated with either IHII,
metallic cation, wherein the first type of naturally
2A9, 3A12, or 3H9 for 2 hours at room temperature. After
occuning polypeptide can bind the metallic cation upon
an acute exposure to the metallic cation;
incubation, the plate was washed and incubated with goat
anti-mouse antibody conjugated with alkaline phosphatase. 45
detecting the amount of the metallic cation bound to one
After incubation, paranitrophenyl phosphate is added and
or more second type of naturally occuning polypeptide
A405 of each well measured after incubation at room
that can bind the metallic cation; wherein the second
temperature of 15-30 minutes. The specificity of each of
type of naturally occuning polypeptide can bind the
these monoclonal antibodies for either glutathione or glumetallic cation after a chronic exposure to the metallic
tathione mercury complex can be confirmed by detecting 50
cation and
immunoreactivity in the ELISA assay.
comparing the amount of the metallic cation bound to the
Monoclonal antibodies specific for glutathione or glufirst type of naturally occuning polypeptide to tne
tathione mercury cations can serve as the antibody specific
amount of metallic cation bound to one or more second
for a naturally occuning polypeptide that binds metallic
type of naturally occuning polypeptide to determine
cation or the antibody specific for an epitope on a metallic 55
whether the exposure to the metallic cation is acute or
cation-naturally occuning polypeptide complex. If the antichronic.
body is specific for both glutathione and glutathione mer8. Tile method according to claim 7, wherein the first type
cury complex, it can be used as an antibody specific for a
of naturally occuning polypeptide is ALAD and the metallic
naturally occurring polypeptide that binds metallic cation. If
cation is lead.
the antibody is only specific for glutathione mercury com- 60
9. The method according to claim 7, wherein the second
plex, then it can be used for an antibody specific for an
type of naturally occuning polypeptide is hemoglobin and
epitope on a metallic cation-naturally occurring polypeptide
the metallic cation is lead.
complex.
10.-The method according to claim 7, wherein the step of
detecting the amount of the metallic cation bound to a first
All patents and publications cited herein are hereby
incorporated by reference. While the present invention has 65 type of naturally occuning polypeptide includes contacting
an effective amount of a first antibody specific for the first
been described in connection with the preferred embodiment
thereof, it will be understood many modifications will be
type of naturally occurring polypeptide with the sample of
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body fluid containing the metallic cation to fonn a first
antigen-antibody complex;
adding an effective amount of a second antibody specific
for an epitope on a metallic cation-first type of naturally
occurring polypeptide complex to the first antigenantibody complex to form a second antigen-antibody
complex, wherein the second antibody does not substantially cross-react with an epitope found on the first
type of naturally occurring polypeptide alone; and
determining the amount of the metallic cation in the body
fluid by detecting the amount of the second antigenantibody complex.
11. A kit for detecting a metallic cation in a sample of a
body fluid from an animal, which comprises:
a first antibody specific for a naturally occurring polypeptide, wherein the polypeptide can bind to the metallic
cation; and
a second antibody specific for the metallic cation.
12. A kit according to claim 11, wherein the first antibody
is immobilized on a substrate.

13. A kit according to claim 11, wherein the second
antibody is labeled by a detectable agent.
14. A kit according to claim 11, wherein the first antibody
is specific for an epitope of a metallic cation-naturally
occurring polypeptide complex.
15. A kit according to claim 14, wherein the first antibody
is specific for an epitope not found on the naturally occurring
polypeptide alone.
16. A kit according to claim 15, wherein the first antibody
does not substantially cross-react with an epitope found in
the naturally occurring polypeptide alone.
17. A kit according to claim 11, wherein the metallic
cation is a lead cation or a mercury cation.
18. A kit according to claim 11, wherein the first antibody
is specific for a naturally occurring polypeptide selected
from the group consisting of I'i-arninolevulinic acid dehydratase (ALAD), hemoglobin, human serum albumin, transferrin, glutathione, and protein kinase C.
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